{"status":"ok","message-type":"work-list","message-version":"1.0.0","message":{"facets":{},"total-results":15,"items":[{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T14:10:35Z","timestamp":1753884635197,"version":"3.41.2"},"reference-count":25,"publisher":"Open Access Pub","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JNA"],"abstract":"Introduction\nHypertension is a major cardiovascular risk factor. There is a strong relationship between blood pressure (BP) elevation and stroke, myocardial infarction, heart failure and mortality due to kidney disease. It is known that the loss of the dipping pattern in hypertension is associated with increased target organ damage. In our study, we aimed to investigate the prevalence of dipper hypertension (DHT) and nondipper hypertension (NDHT) and related factors in patients with stage 1 and 2 chronic kidney disease (CKD).\n\nMaterials and Methods\nA total of 158 patients diagnosed with stage 1 or stage 2 CKD were included in the study. Demographic characteristics, anthropometric measurements, physical examination findings and laboratory results of the patients were recorded. Ambulatory BP monitoring was performed in all patients.\n\nResults\nOf the 158 patients (female n: 98), 78 (49%) were in the stage 1 CKD group and 80 (51%) were in the stage 2 CKD group. No significant difference was observed in the prevalence of DHT or NDHT between hypertensive patients in the stage 1 and 2 CKD groups. The rate of NDHT was 59.5% (94\/158 patients). Female patients had more DHT in the general population and in the stage 1 group than male patients (p=0.05, p=0.01, respectively).\n\nConclusion\nNo significant difference was observed in the prevalence of DHT or NDHT between hypertensive patients in the stage 1 and 2 CKD groups. The prevalence of DHT in female patients was significantly higher in both groups than in men in both groups, but especially in the stage 1 CKD group.<\/jats:p>","DOI":"10.14302\/issn.2574-4488.jna-19-3008","type":"journal-article","created":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T07:03:25Z","timestamp":1569308605000},"page":"15-23","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of Dipper and Non-Dipper Hypertension Patterns According to Chronic Kidney Disease Stage"],"prefix":"10.14302","volume":"1","author":[{"given":"Esra Turan","family":"Erkek","sequence":"first","affiliation":[{"name":"University of Health Sciences, Dr Lutfi Kirdar Training and Research Hospital, Department of Internal Medicine, Istanbul, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seydahmet","family":"Akin","sequence":"additional","affiliation":[{"name":"University of Health Sciences, Dr Lutfi Kirdar Training and Research Hospital, Department of Internal Medicine, Istanbul, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasemin","family":"Ozgur","sequence":"additional","affiliation":[{"name":"University of Health Sciences, Dr Lutfi Kirdar Training and Research Hospital, Department of Internal Medicine, Istanbul, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeki","family":"Aydin","sequence":"additional","affiliation":[{"name":"Darica Training and Research Hospital. Department of Nephrology, Kocaeli, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zerrin","family":"Bicik","sequence":"additional","affiliation":[{"name":"University of Health Sciences, Dr Lutfi Kirdar Training and Research Hospital, Department of Nephrology, Istanbul, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5410","published-online":{"date-parts":[[2019,9,24]]},"reference":[{"key":"ref0","unstructured":"1.KilickapM BarcinC, GoksulukH KaraaslanD, Ozer N. (2018) Data on prevalence of hypertension and blood pressurein Turkey: Systematic review, metaanalysis and metaregression of epidemiological studies on cardiovascular risk factors. doi: 10.5543\/tkda.2018.15679.TurkKardiyolDern Ars. 46(7), 525-545."},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2.SonmezA HaymanaC, Bayram F, Salman S, Dizdar O S.(2018)TEMD Study Group. Turkish nationwide survEy of glycemic and other Metabolic parameters of patients with Diabetes mellitus (TEMD study). doi: 10.1016\/j.diabres.2018.09.010..Diabetes Res ClinPract. 146, 138-147.","DOI":"10.1016\/j.atherosclerosis.2018.06.156"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3.Altun B, Suleymanlar G, Utas C, Arinsoy T, Ates K et al. (2012) . Prevalence, Awareness, Treatment and Control of Hypertension in Adults with Chronic Kidney Disease in Turkey: Results from the CREDIT Study. doi: 10.1159\/000339025. Kidney Blood Press Res 36, 36-46.","DOI":"10.1159\/000339025"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4.Neal B, MacMahon S, Chapman N. (2000) Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs. , Lancet 356, 1955-1964.","DOI":"10.1016\/s0140-6736(00)03307-9"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5.Montalescot Gilles, Collet Jean-Philippe. (2005) Preserving cardiac function in the hypertensive patient: why renal parameters hold the key, doi: https:\/\/doi.org\/10.1093\/eurheartj\/ehi414. , European Heart Journal 26, 2616-2622.","DOI":"10.1093\/eurheartj\/ehi414"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6.Wenzel R R. (2005) Renal Protection in Hypertensive Patients: Selection of Antihypertensive Therapy. , Drugs 2(2), 29-39.","DOI":"10.2165\/00003495-200565002-00005"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.Lewis J B. (2003) Treatment of diabetic nephropathy with angiotensin II receptor antagonist. doi:https:\/\/doi.org\/10.1007\/s101570300000. Clin Exp Nephrol 7, 1-8.","DOI":"10.1007\/s101570300000"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8.Weiner D E, Tighiouart H, Stark P C, Amin M G, MacLeod B. (2004) Chronic Kidney Disease as a Risk Factor for Cardiovascular Disease and All-Cause Mortality: A Pooled Analysis of Community-Based Studies. doi: 10.1097\/01.ASN.0000123691.46138.E2. Am J Kidney Dis.15: 1307-1315.","DOI":"10.1097\/01.asn.0000123691.46138.e2"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9.Lin L, Zhang H, Yang J, Zhang J, Li K. (2016) . Nocturnal and Circadian Rhythm of Blood Pressure Is Associated with Renal Structure Damage and Function in Patients with IgAN. doi: 10.1016\/j.arcmed.2016.01.001.Arch Med Res 47, 25-32.","DOI":"10.1016\/j.arcmed.2016.01.001"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10.Hermida R C, Ayala D E, Fern\u00e1ndez J R, Moj\u00f3n A. (2013) Sleep-time blood pressure: prognostic value and relevance as a therapeutic target for cardiovascular risk reduction. doi: 10.3109\/07420528.2012.702581. , Chronobiol Int 30, 68-86.","DOI":"10.3109\/07420528.2012.702581"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11.Kim B K, Lim Y H, Lee H T, Lee J U, Kim K S. (2011) . Non-Dipper Pattern is a Determinant of the Inappropriateness of Left Ventricular Mass in Essential Hypertensive Patients. doi: 10.4070\/kcj.2011.41.4.191. Korean Circ J 41, 191-7.","DOI":"10.4070\/kcj.2011.41.4.191"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12.Disease Kidney. (2012) Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO. , Kidney Int Suppl 3, 1-150.","DOI":"10.1016\/j.kisu.2017.10.001"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13.Seo W S, Oh H S. (2002) The circadian rhythms of blood pressure and heart rate in the hypertensive subjects: dippers and non-dippers. doi: 10.3349\/ymj.2002.43.3.320. , Yonsei Med J 43, 320-328.","DOI":"10.3349\/ymj.2002.43.3.320"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14.Pierdomenico S D, Costantini F, Bucci A, D, Bucciarelli T. (1999) Blunted nocturnal fall in blood pressure and oxidative stress in men and women with essential hypertension. , Am J Hypertens 12, 356-363.","DOI":"10.1016\/s0895-7061(00)86961-7"},{"key":"ref14","unstructured":"15.Verdecchia P, Schillaci G, Porcellati C. (1991) Dippers versus non-dippers. , J Hypertens Suppl 9, 42-44."},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16.O\u2019Brien E, Sheridan J, O\u2019Malley K. (1988) Dippers and non-dippers. , Doi:https:\/\/doi.org\/10.1016\/S0140-6736(88)92867-X. Lancet 2, 397.","DOI":"10.1016\/s0140-6736(88)92867-x"},{"key":"ref16","unstructured":"17.Ersoylu Z D, Tugcu A, Yildirimturk O, Aytekin V, Aytekin S. (2008) Comparison of the incidences of left ventricular hypertrophy, left ventricular diastolic dysfunction, and arrhythmia between patients with dipper and non-dipper hypertension.Turk Kardiyol Dern Ars. 36, 310-317."},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18.Redon J, Plancha E, Swift P A, Pons S, Mu\u00f1oz J. (2010) Nocturnal blood pressure and progression to end-stage renal disease or death in nondiabetic chronic kidney disease stages 3 and 4. doi: 10.1097\/HJH.0b013e328333fe4d. , J Hypertens 28, 602-607.","DOI":"10.1097\/hjh.0b013e328333fe4d"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19.Agarwal R, Anderson M J. (2006) Prognostic importance of ambulator blood pressure recordings in patients with chronic kidney disease. doi: 10.1038\/sj.ki.5000247. , Kidney Int 69, 1175-1180.","DOI":"10.1038\/sj.ki.5000247"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20.Kobrin I, Oigman W, Kumar A, Ventura H O, Messerli F H. (1984) Diurnal variation of blood pressure in elderly patients with essential hypertension. , J Am Geriatr Soc 2, 896-899.","DOI":"10.1111\/j.1532-5415.1984.tb00890.x"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21.Minutolo R, Agarwal R, Borrelli S, Chiodini P, Bellizzi V. (2011) . Prognostic Role of Ambulatory Blood Pressure Measurement in Patients With Nondialysis Chronic Kidney Disease. doi: 10.1001\/archinternmed.2011.230. Arch Intern Med 171, 1090-1098.","DOI":"10.1001\/archinternmed.2011.230"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22.Cuspidi C, Meani S, Valerio C, Sala C, Fusi V. (2007) Reproducibility of dipping\/nondipping pattern in untreated essential hypertensive patients: impact of sex and age. doi: 10.1097\/MBP.0b013e32809efa51. Blood Press Monit. 12, 101-106.","DOI":"10.1097\/mbp.0b013e32809efa51"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23.CuspidiC MeaniS, Valerio C, Negri F, Sala C. (2008) Body mass index, nocturnal fall in blood pressure and organ damage in untreated essential hypertensive patients. doi: 10.1097\/MBP.0b013e32830d4bf8.Blood PressMonit. 13(6), 318-24.","DOI":"10.1097\/mbp.0b013e32830d4bf8"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24.An H R, Park S, Yoo T H, Kang S W, Ryu J H. (2011) Non-dipper status and left ventricular hypertrophy as predictors of incident chronic kidney disease. doi: 10.3346\/jkms.2011.26.9.1185. , J Korean Med Sci 26, 1185-1190.","DOI":"10.3346\/jkms.2011.26.9.1185"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25.Tonelli M, Wiebe N, Culleton B, House A, RabbatC. (2006) Chronic kidney disease and mortality risk: a systematic review.J Am SocNephrol. 17, 2034-2047.","DOI":"10.1681\/ASN.2005101085"}],"container-title":["Journal of Nephrology Advances"],"link":[{"URL":"https:\/\/openaccesspub.org\/jna\/article\/1170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T07:03:36Z","timestamp":1569308616000},"score":0.0,"resource":{"primary":{"URL":"https:\/\/openaccesspub.org\/jna\/article\/1170"}},"editor":[{"given":"Elbaih","family":"Zico","sequence":"additional","affiliation":[{"name":"Suez Canal University, Ismailia, Egypt."}],"role":[{"role":"editor","vocabulary":"crossref"}]}],"issued":{"date-parts":[[2019,9,24]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,10,12]]}},"URL":"https:\/\/doi.org\/10.14302\/issn.2574-4488.jna-19-3008","ISSN":["2574-4488"],"issn-type":[{"type":"electronic","value":"2574-4488"}],"published":{"date-parts":[[2019,9,24]]},"article-number":"1170"},{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:31:39Z","timestamp":1777494699018,"version":"3.51.4"},"reference-count":17,"publisher":"Open Access Pub","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JNA"],"abstract":"Introduction\nIncreased oxidative stress and blunted anti-oxidant mechanisms are important problems in hemodialysis (HD) patients. Reactive oxygen species (ROS) act directly on proteins, leading to the formation of oxidized amino acids. Advanced oxidation protein products (AOPP) are among these substances. Many oxidant substances increase the level of AOPP. Iron is an element with strong oxidant capacity, especially when used intravenously. It is thought that iron treatment further increases the oxidative stress in HD patients. We aimed to investigate the relationship between AOPP and inflammatory status in HD patients.\n\nMaterials and Methods\nPatients who were on maintenance HD program without additional co-morbidities and no history of use of intravenous iron within the last two weeks were recruited in the study. The blood samples taken just before the dialysis session were analyzed for AOPP, serum iron, total iron binding capacity (TIBC), ferritin, C-reactive protein (CRP), \u00df2-microglobulin, fibrinogen, interleukin (IL)-1, IL-6 and tumor necrosis factor-\u03b1 levels besides routine biochemical measurements and complete blood count.\n\nResults\nThe number of patients included in the study was 102 (n: 53 female, %52.0) and the mean age was 47.6\u00b113.9 years. The mean transferrin saturation was 25.4%. AOPP levels, iron use in patients was higher compared to patients who do not use (respectively 2.58\u00b10.19 mmol\/l and 2.50 \u00b10.16mmol\/l, p = 0.046). We did not detect statistically significant correlation of AOPP levels with iron parameters and other inflammatory markers.\n\nConclusion\nThe present study showed that intravenous iron therapy does not increase oxidative stress. Although serum AOPP level was higher in patients on intravenous iron treatment, it was not correlated with iron indices and inflammatory markers. So, intravenous iron may exert its oxidant effect free from serum iron indices.<\/jats:p>","DOI":"10.14302\/issn.2574-4488.jna-19-3112","type":"journal-article","created":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T10:20:17Z","timestamp":1577355617000},"page":"24-30","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of the Relationship Between Advanced Oxidation end Products and Inflammatory Markers in Maintenance Hemodialysis Patients"],"prefix":"10.14302","volume":"1","author":[{"given":"Zeki","family":"Aydin","sequence":"first","affiliation":[{"name":"Darica Farabi Training and Research Hospital, Department of Nephrology, Kocaeli, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serhat","family":"Karadag","sequence":"additional","affiliation":[{"name":"Haseki Training and Research Hospital, Department of Nephrology, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savas","family":"Ozturk","sequence":"additional","affiliation":[{"name":"Haseki Training and Research Hospital, Department of Nephrology, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meltem","family":"Gursu","sequence":"additional","affiliation":[{"name":"Bezmialem Vakif University Hospital, Department of Nephrology, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sami","family":"Uzun","sequence":"additional","affiliation":[{"name":"Haseki Training and Research Hospital, Department of Nephrology, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Egemen","family":"Cebeci","sequence":"additional","affiliation":[{"name":"Haseki Training and Research Hospital, Department of Nephrology, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Sumnu","sequence":"additional","affiliation":[{"name":"Haseki Training and Research Hospital, Department of Nephrology, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rumeyza","family":"Kazancioglu","sequence":"additional","affiliation":[{"name":"Bezmialem Vakif University Hospital, Department of Nephrology, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5410","published-online":{"date-parts":[[2019,12,25]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1.Cavdar C, Camsari T, Semin I, Gonen S, Ac\u0131kgoz O. (1997) Lipid peroxidation and antioxidant activity in chronic haemodialysis patients treated with recombinant human erythropoietin. , Scand J Urol Nephrol 31, 371-75.","DOI":"10.3109\/00365599709030622"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2.Herbelin A, Nguyen A T, Zingraff J, Urena P, Descamps-Latscha B. (1990) Influence of uremia and hemodialysis on circulation interleukin-1 and tumor necrosis factor alpha. , Kidney Int 37, 116-25.","DOI":"10.1038\/ki.1990.16"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.Lander H. (1997) An essentiol role for free radicals and derived species in signal transduction. , FASEB J 11, 118-24.","DOI":"10.1096\/fasebj.11.2.9039953"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4.Gil-del Valle L, L de la C Milian, Toledo A, Vilar\u00f3 N, T\u00e1panes R et al. (2005) Altered redox status in patients with Diabetes Mellitus Type 1. , Pharmacological Research 51, 375-80.","DOI":"10.1016\/j.phrs.2004.10.012"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5.Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen A T et al. (1996) Advanced oxidation protein products as a novel marker of oxidative stres in uremia. , Kidney Int 49, 1304-13.","DOI":"10.1038\/ki.1996.186"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6.Lim P S, Wei Y H, Yu Y L, Kho B. (1999) Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. , Nephrol Dial Transplant 14, 2680-87.","DOI":"10.1093\/ndt\/14.11.2680"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7.Kumbasar A, Gursu M, Kaya C, Ozturk S, Ergen A et al. (2012) effect of different doses and types of intravenous iron on oxidative stress and inflammation in hemodialysis patients.J. , Nephrol 25, 825-32.","DOI":"10.5301\/jn.5000072"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8.Delmas-Beauvieux M C, Combe C, Peuchant E, Carbonneau M A, Dubourg L et al. (1995) Evaluation of red blood cell lipoperoxidation in hemodialysis patients during erythropoietin therapy supplemented or not with iron. , Nephron 69, 404-10.","DOI":"10.1159\/000188510"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9.Stenvinkel P, Heimburger O, Lindholm B, Kaysen G A, Bergstr\u00f6m J. (2000) Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). , Nephrol Dial Transplant 15, 953-60.","DOI":"10.1093\/ndt\/15.7.953"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10.Richard M, Arnaud J, Jurkovitz C, Hachache T, Meftahi H et al. (1991) Trace elements and lipid perokxidation abnormalities in patiets with chronic renal failure. , Nephron 57, 10-15.","DOI":"10.1159\/000186208"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11.Matkovics B, Laszlo A, Varga S I, Gal G, Solymosi T. (1998) Changes and correlations of antioxidant enzymes, lipid peroxidation and serum neutral lipids due to hemodialysis treatment in chronic ureamic patients. , Int Urol Nephrol 20, 559-64.","DOI":"10.1007\/bf02550619"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.Coskun C, Kural A, Doventas Y, Koldas M, Ozturk H et al. (2007) and protein oxidation products.Ann. , N Y Acad Sci 1100, 404-08.","DOI":"10.1196\/annals.1395.045"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13.Colombo G, Reggiani F, Astori E, Altomare A, Finazzi S et al. (2019) Advanced oxidation protein products in nondiabetic end stage renal disease patients on maintenance haemodialysis. Free Radic Res. 22, 1-11.","DOI":"10.1080\/10715762.2019.1690651"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14.Xu H, Cabezas-Rodriguez I, Qureshi A R, Heimburger O, Barany P et al. (2015) Increased Levels of Modified Advanced Oxidation Protein Products Are Associated with Central and Peripheral Blood Pressure in Peritoneal Dialysis Patients. Perit Dial Int. 35(4), 460-70.","DOI":"10.3747\/pdi.2013.00064"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15.Dr\u00fceke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin A P et al. (2002) therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease.Circulation. 106, 2212-17.","DOI":"10.1161\/01.cir.0000035250.66458.67"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16.Heimburger O, Qureshi A R, Blaner W S, Berglund L, Stenvinkel P. (2000) Hand-grip muscle strength, lean body mass, and plasma proteins as marker of nutritional status in patients with chronic renal failure close to start to dialysis therapy. , Am J Kidney Dis 6, 1213-25.","DOI":"10.1053\/ajkd.2000.19837"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.Stenvinkel P. (2001) The role of inflammation in the anaemia of endstage renal disease. , Nephrol Dial Transplant 1, 36-40.","DOI":"10.1093\/ndt\/16.suppl_7.36"}],"container-title":["Journal of Nephrology Advances"],"link":[{"URL":"https:\/\/openaccesspub.org\/jna\/article\/1229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T10:20:36Z","timestamp":1577355636000},"score":0.0,"resource":{"primary":{"URL":"https:\/\/openaccesspub.org\/jna\/article\/1229"}},"editor":[{"given":"Syed Arshad","family":"Hussain","sequence":"additional","affiliation":[{"name":"Tripura Universit, India."}],"role":[{"role":"editor","vocabulary":"crossref"}]}],"issued":{"date-parts":[[2019,12,25]]},"references-count":17,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,10,12]]}},"URL":"https:\/\/doi.org\/10.14302\/issn.2574-4488.jna-19-3112","ISSN":["2574-4488"],"issn-type":[{"value":"2574-4488","type":"electronic"}],"published":{"date-parts":[[2019,12,25]]},"article-number":"1229"},{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T14:11:14Z","timestamp":1753884674329,"version":"3.41.2"},"reference-count":15,"publisher":"Open Access Pub","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JNA"],"abstract":"Primary membranous nephropathy (MN) is due to autoantibodies to phospholipase A2 receptor (PLA2R Ab). It is unclear whether COVID-19 vaccines can trigger flares of glomerular diseases such as primary MN. There have been increasing reports of glomerular diseases presenting or flaring after receipt of COVID-19 vaccines. We present a patient with primary MN who developed nephrotic syndrome after receiving her second mRNA-1273 COVID-19 vaccine with positive PLA2R Ab. Renal biopsy confirmed primary MN. She was treated for her primary MN flare with rituximab in a manner similar to non-vaccine-associated MN, which led to significant reduction in both PLA2R Ab level and proteinuria. This case adds to the growing literature on MN flares after receipt of mRNA COVID-19 vaccines. Close follow-up of patients with primary MN and other glomerular diseases after COVID-19 vaccination is warranted. Further research is needed to determine the pathophysiology behind vaccine-induced MN flares and whether there is a potential association between exposure to SARS-CoV-2 antigens and loss of tolerance to the PLA2R antigen.<\/jats:p>","DOI":"10.14302\/issn.2574-4488.jna-24-5219","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T09:40:37Z","timestamp":1728294037000},"page":"12-18","source":"Crossref","is-referenced-by-count":0,"title":["Primary Membranous Nephropathy Flare After COVID-19 Vaccination"],"prefix":"10.14302","volume":"1","author":[{"given":"Kelly","family":"V. Liang","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Nephrology and Hypertension, Jared Grantham Kidney Institute, University of Kansas Medical Center, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syeda","family":"B. Ahmad","sequence":"additional","affiliation":[{"name":"Department of Medicine, Renal-Electrolyte Division, University of Pittsburgh Medical Center, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"C. Kurtz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Renal-Electrolyte Division, University of Pittsburgh Medical Center, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Pittappilly","sequence":"additional","affiliation":[{"name":"Department of Medicine, Renal-Electrolyte Division, University of Pittsburgh Medical Center, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"I. Minervini","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Pittsburgh Medical Center, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5410","published-online":{"date-parts":[[2024,9,5]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1.Kutlucan A, Gonen I, Yildizhan E. (2012) Can influenza H1N1 vaccination lead to the membranous glomerulonephritis?. , Indian Journal of Pathology & Microbiology 55(2), 239-241.","DOI":"10.4103\/0377-4929.97893"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2.Patel C, Shah H H. (2015) Membranous nephropathy and severe acute kidney injury following influenza vaccination. , Saudi Journal of Kidney Diseases 26-6.","DOI":"10.4103\/1319-2442.168676"},{"key":"ref2","unstructured":"3.Palevsky P M, Radhakrishnan J, Townsend R R. (2022) COVID-19: Issues related to acute kidney injury, glomerular disease, and hypertension. UpToDate."},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4.Klomjit N, Alexander M P, Fervenza F C. (2021) COVID-19 Vaccination and Glomerulonephritis. Kidney Int Rep. 6(12), 2969-2978.","DOI":"10.1016\/j.ekir.2021.09.008"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5.HHL Wu, Kalra P A, Chinnadurai R. (2021) New-Onset and Relapsed Kidney Histopathology Following COVID-19 Vaccination: A Systematic Review. Vaccines (Basel). , Oct29; 9(11), 1252.","DOI":"10.3390\/vaccines9111252"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6.Izzedine H, Bonilla M, Jhaveri K D. (2021) Nephrotic syndrome and vasculitis following SARS-CoV-2 Vaccine: True association or circumstantial? Nephrol Dial Transplant. 10, 215.","DOI":"10.1093\/ndt\/gfab215"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7.Anderegg M A, Liu M, Saganas C.et al.(2021).De novo vasculitis after mRNA-1273 (Moderna)vaccination. Kidney Int.100:. 474.","DOI":"10.1016\/j.kint.2021.05.016"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8.Sekar A, Campbell R, Tabbara J. (2021) . ANCA Glomerulonephritis post Moderna COVID-19 vaccination. Kidney Int 100(2), 473-474.","DOI":"10.1016\/j.kint.2021.05.017"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9.Shakoor M T, Birkenbach M P, Lynch M. (2021) ANCA-associated vasculitis following Pfizer-BioNTech COVID-19 vaccine. Am J Kidney Dis. 78, 611-613.","DOI":"10.1053\/j.ajkd.2021.06.016"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10.Weijers J, Alvarez C, MMH Hermans. (2021) Post-vaccinal minimal change disease. Kidney Int. 100(2), 459-461.","DOI":"10.1016\/j.kint.2021.06.004"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11.Da Y, Goh G H, Khatri P. (2021) A case of membranous nephropathy following Pfizer-BioNTech mRNA vaccination against COVID-19. Kidney Int. 100(4), 938-939.","DOI":"10.1016\/j.kint.2021.07.016"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12.Gueguen L, Loheac C, Saidani N. (2021) Membranous nephropathy following anti-COVID-19 mRNA vaccination. Kidney Int. 100(5), 1140-1141.","DOI":"10.1016\/j.kint.2021.08.006"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13.Ayd\u0131n M F, Y\u0131ld\u0131z A, Oru\u00e7 A. (2021) Relapse of primary membranous nephropathy after inactivated SARS-CoV-2 virus vaccination. Kidney Int. 100(2), 464-465.","DOI":"10.1016\/j.kint.2021.05.001"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14.Li N L, Coates P T, Rovin B H. (2021) COVID-9 vaccination followed by activation of glomerular diseases: does association equal causation? Kidney Int. 100-959.","DOI":"10.1016\/j.kint.2021.09.002"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15.Bomback A S, Kudose S.D'Agati VD.(2021).De Novo and Relapsing Glomerular Diseases After COVID-19 Vaccination: What Do We Know So Far?. , Am J Kidney Dis.78: 477.","DOI":"10.1053\/j.ajkd.2021.06.004"}],"container-title":["Journal of Nephrology Advances"],"link":[{"URL":"https:\/\/openaccesspub.org\/jna\/article\/2165","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T09:40:43Z","timestamp":1728294043000},"score":0.0,"resource":{"primary":{"URL":"https:\/\/openaccesspub.org\/jna\/article\/2165"}},"issued":{"date-parts":[[2024,9,5]]},"references-count":15,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,5,15]]}},"URL":"https:\/\/doi.org\/10.14302\/issn.2574-4488.jna-24-5219","ISSN":["2574-4488"],"issn-type":[{"type":"electronic","value":"2574-4488"}],"published":{"date-parts":[[2024,9,5]]},"article-number":"2165"},{"indexed":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T04:11:32Z","timestamp":1728360692358},"reference-count":0,"publisher":"Open Access Pub","content-domain":{"domain":[],"crossmark-restriction":false},"DOI":"10.14302\/issn.2574-4488","type":"journal","created":{"date-parts":[[2017,9,10]],"date-time":"2017-09-10T06:21:28Z","timestamp":1505024488000},"source":"Crossref","is-referenced-by-count":1,"title":["Journal of Nephrology Advances"],"prefix":"10.14302","member":"5410","deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T09:40:38Z","timestamp":1728294038000},"score":0.0,"resource":{"primary":{"URL":"http:\/\/openaccesspub.org\/journal\/jna"}},"short-title":["JNA"],"issued":{"date-parts":[[null]]},"references-count":0,"URL":"https:\/\/doi.org\/10.14302\/issn.2574-4488","ISSN":["2574-4488"],"issn-type":[{"type":"electronic","value":"2574-4488"}]},{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T07:28:07Z","timestamp":1649143687817},"reference-count":39,"publisher":"Open Access Pub","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JNA"],"abstract":"The aim of this study was to evaluate the impact of Biofield Energy Treated\/Blessed Proprietary Test Formulation and Biofield Energy Treatment\/Blessing per se on kidney biomarkers on L-NAME and high fat diet (HFD)-induced cardiovascular disorders in Sprague Dawley rats. In this experiment, the functional kidney biomarkers such as epinephrine\/adrenaline, inducible nitric oxide synthase (iNOS), angiotensin-II, C-reactive protein (CRP), and renin were measured using ELISA assay. A test formulation was formulated including minerals (magnesium, zinc, copper, calcium, selenium, and iron), vitamins (vitamin C, vitamin B6, vitamin B12, vitamin B9, and vitamin D3), cannabidiol (CBD) isolate, Panax ginseng extract, and \u03b2-carotene. The components of the test item were divided into two; one section was defined as the untreated test formulation, while the other part and three group of animals received Mr. Mahendra Kumar Trivedi\u2019s Biofield Energy healing\/Blessing remotely for about 3 minutes. The results showed that the level of adrenaline was reduced by 31.62%, 19.58%, 34.32%, 37.07%, and 29.87% in the G5 (L-NAME + HFD + the Biofield Energy Treated test formulation), G6 (L-NAME + HFD + Biofield Energy Treatment per se to animals from day -15), G7 (L-NAME + HFD + the Biofield Energy Treated test formulation from day-15), and G8 (L-NAME + HFD + Biofield Energy Treatment per se plus the Biofield Energy Treated test formulation from day-15), and G9 (L-NAME + HFD + Biofield Energy Treatment per se animals plus the untreated test formulation) groups, respectively as compared to the disease control group (G2). Moreover, the level of iNOS was reduced by 56.76%, 49.51%, 61.79%, 57.63%, and 62.44% in the G5, G6, G7, G8, and G9 groups, respectively, as compared to the disease control group (G2). Additionally, the level of angiotensin-II was decreased by 41.09%, 34.92%, 60.65%, 53.28%, and 60.09% in the G5, G6, G7, G8, and G9 groups, respectively, as compared to the G2 group. The level of CRP was decreased by 47.21%, 38.89%, 59.81%, 55.52%, and 64.02% in the G5, G6, G7, G8, and G9 groups, respectively as compared to the G2 group. Besides, the level of renin was decreased by 20.27%, 20.13%, 12.99%, and 25.73% in the G5, G7, G8, and G9 groups, respectively as compared to the G2 group. Overall, the data suggested significance improvement of vital functional kidney biomarkers of the Biofield Energy Treated\/Blessed test formulation and Biofield Energy Treatment per se along with preventive measure on the animal with respect to various pathological conditions that might be beneficial various types of cardiovascular disorders. Therefore, the results showed the significant slowdown the inflammation-related cardiovascular disease progression and its complications\/symptoms in the preventive Biofield Energy Treatment group per se and\/or Biofield Energy Treated\/Blessed Test formulation groups (viz. G6, G7, G8, and G9).<\/jats:p>","DOI":"10.14302\/issn.2574-4488.jna-21-3847","type":"journal-article","created":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T10:12:35Z","timestamp":1627726355000},"page":"12-22","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Renal and Cardioprotective Potential of the Biofield Energy Treated Proprietary Test Formulation on L-NAME and High Fat Diet-Induced Cardiovascular Disorders in Sprague Dawley Rats"],"prefix":"10.14302","volume":"1","author":[{"given":"Mahendra Kumar","family":"Trivedi","sequence":"first","affiliation":[{"name":"Trivedi Global, Inc., Henderson, Nevada, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Branton","sequence":"additional","affiliation":[{"name":"Trivedi Global, Inc., Henderson, Nevada, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dahryn","family":"Trivedi","sequence":"additional","affiliation":[{"name":"Trivedi Global, Inc., Henderson, Nevada, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Snehasis","family":"Jana","sequence":"additional","affiliation":[{"name":"Trivedi Science Research Laboratory Pvt. Ltd., Thane (W), Maharashtra, India."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5410","published-online":{"date-parts":[[2021,6,26]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1.Clifton W Callaway. (2013) Epinephrine for cardiac arrest. , Current Opinion in Cardiology 28(1), 36-42.","DOI":"10.1097\/hco.0b013e32835b0979"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2.Tsutsui M, Shimokawa H, Otsuji Y, Ueta Y, Sasaguri Y et al. (2009) Nitric oxide synthases and cardiovascular diseases: Insights from genetically modified mice. , Circ J 73(6), 986-993.","DOI":"10.1253\/circj.cj-09-0208"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.Besedina A. (2016) NO-synthase activity in patients with coronary heart disease associated with hypertension of different age groups. , J Med Biochem 35(1), 43-49.","DOI":"10.1515\/jomb-2015-0008"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4.Ferrario C M. (2006) Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research.J. , Renin Angiotensin Aldosterone Syst 7(1), 3-14.","DOI":"10.3317\/jraas.2006.003"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5.Lemari\u00e9 C A, Schiffrin E L. (2010) The angiotensin II type 2 receptor in cardiovascular disease. , J Renin Angiotensin Aldosterone Syst 11(1), 19-31.","DOI":"10.1177\/1470320309347785"},{"key":"ref5","unstructured":"6.Cozlea D L, Farcas D M, Nagy A. (2013) The impact of C reactive protein on global cardiovascular risk on patients with coronary artery disease. , Curr Health Sci J 39(4), 225-231."},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7.Lagrand W K, Visser C A, Hermens W T, Niessen H W, Verheugt F W et al. (1991) C-reactive protein as a cardiovascular risk factor: More than an epiphenomenon?. , Circulation 100(1), 96-102.","DOI":"10.1161\/01.cir.100.1.96"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8.Lambers Heerspink HJ, Perkovic V, D de Zeeuw. (2009) Renal and cardio-protective effects of direct renin inhibition: A systematic literature review. , J Hypertens 27(12), 2321-2331.","DOI":"10.1097\/hjh.0b013e3283310f92"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9.Byrne J H, Voogt M, Turner K M, Eyles D W, McGrath J J et al. (2013) The impact of adult vitamin D deficiency on behaviour and brain function in male Sprague-Dawley rats. , PLoS One 8(8), 71593.","DOI":"10.1371\/journal.pone.0071593"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.Rayman M P. (2000) The importance of selenium to human health. , Lancet 356, 233-241.","DOI":"10.1016\/S0140-6736(00)02490-9"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.Beard J L, Connor J R. (2003) Iron status and neural functioning. , Ann Rev Nutr 23, 41-58.","DOI":"10.1146\/annurev.nutr.23.020102.075739"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12.Peres F F, Lima A C, JEC Hallak, Crippa J A, Silva R H.Ab\u00edlio VC (2018) Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders? Front Pharmacol 9:. 482.","DOI":"10.3389\/fphar.2018.00482"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13.Nagarkatti P, Pandey R, Rieder S A, Hegde V L, Nagarkatti M. (2009) Cannabinoids as novel anti-inflammatory drugs. , Future Med Chem 1(7), 1333-1349.","DOI":"10.4155\/fmc.09.93"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14.Kang S, Min H. (2012) Ginseng, the 'Immunity Boost': The effects ofPanax ginsengon immune system. , J Ginseng Res 36(4), 354-368.","DOI":"10.5142\/jgr.2012.36.4.354"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15.Maizes V, Rakel D, Niemiec C. (2009) Integrative medicine and patient-centered care. , Explore (NY) 5(5), 277-289.","DOI":"10.1016\/j.explore.2009.06.008"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16.Bischof M, Del Giudice E. (2013) Communication and the emergence of collective behavior in living organisms: A quantum approach. Mol Biol Int. 987549.","DOI":"10.1155\/2013\/987549"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.Cassidy C M. (2004) What does it mean to practice an energy medicine?. , J Altern Complement Med 10(1), 79-81.","DOI":"10.1089\/107555304322848986"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18.Barnes P M, Bloom B, Nahin R L. (2008) Complementary and alternative medicine use among adults and children: United States. , Natl Health Stat Report 12, 1-23.","DOI":"10.1037\/e623942009-001"},{"key":"ref18","unstructured":"19.Fan K wai. (2005) National Center for Complementary and Alternative Medicine Website. , J Med Libr Assoc 93, 410-412."},{"key":"ref19","unstructured":"20.Wisneski L, Anderson L. (2009) The Scientific Basis of Integrative Medicine. , Boca Raton, FL: 205."},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21.Trivedi M K, Branton A, Trivedi D, Jana S. (2021) Isotopic abundance ratio analysis of consciousness energy healing treated folic acid. , Food Nutr Current Res 4(2), 290-295.","DOI":"10.14302\/issn.2576-6694.jbbs-21-3773"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22.Trivedi M K, Branton A, Trivedi D, Nayak G, Mondal S C et al. (2015) Morphological characterization, quality, yield and DNA fingerprinting of biofield energy treated alphonso mango (Mangifera indicaL.). , Journal of Food and Nutrition Sciences 3, 245-250.","DOI":"10.11648\/j.jfns.20150306.18"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23.Mahendra Kumar Trivedi.Snehasis Jana (2019)In vitroassessment of the biofield treated test item on cardiac function using rat cardiomyocytes cell line (H9c2)viamultiparametric analysis. , Journal of Hypertension and Cardiology 2(4), 1-12.","DOI":"10.14302\/issn.2329-9487.jhc-19-2582"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24.Trivedi M K, Branton A, Trivedi D, Jana S. (2021) Effect of consciousness energy healing treatment on the metal profile and properties of tellurium. , Eng Technol Open Acc 3(5), 555623.","DOI":"10.19080\/ETOAJ.2021.03.555623"},{"key":"ref24","unstructured":"25.Mahendra K T, Alice B, Dahryn T, Snehasis J. (2021) Consciousness energy healing treatment impacted the isotopic abundance ratio of 6-Mercaptopurine (6-MP). Nov Appro Drug Des Dev. 5(5), 555673."},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26.Trivedi M K, Jana S. (2021) Anti-aging activity of biofield energy treated novel proprietary test formulation by assessment of vital biomarkers in cerebrospinal fluid (CSF) in Sprague Dawley rats. , On J Neur & Br Disord 5(2).","DOI":"10.23880\/aabsc-16000163"},{"key":"ref26","unstructured":"27.Trivedi M K, Jana S. (2021) Evaluation of biofield energy healing treatment based proprietary test formulation on gut health potential in colon cancer cell line (HT-29). , J Pharmacol Clin Res 8(4), 555743."},{"key":"ref27","unstructured":"28.Trivedi M K, Branton A, Trivedi D, Jana S. (2020) The consciousness energy healing treatment and its impact on the isotopic abundance ratio analysis of flutamide. , Drug Des Int Prop Int J 3(5)."},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29.C de Lucia, Femminella G D, Gambino G. (2014) Adrenal adrenoceptors in heart failure. , Front Physiol 5, 246.","DOI":"10.3389\/fphys.2014.00246"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30.Tang E H, Vanhoutte P M. (2010) Endothelial dysfunction: A strategic target in the treatment of hypertension?. , Pflugers Arch 459(6), 995-1004.","DOI":"10.1007\/s00424-010-0786-4"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31.Raddino R, Caretta G, Teli M, Bonadei I, Robba D et al. (2007) Nitric oxide and cardiovascular risk factors. , Heart international 3(1), 18.","DOI":"10.4081\/hi.2007.18"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"32.Besedina A. (2016) NO-Synthase activity in patients with coronary heart disease associated with hypertension of different age groups. , J Med Biochem 35(1), 43-49.","DOI":"10.1515\/jomb-2015-0008"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33.Ferrario C M. (2006) Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. , J Renin Angiotensin Aldosterone Syst 7(1), 3-14.","DOI":"10.3317\/jraas.2006.003"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"34.Lemari\u00e9 C A, Schiffrin E L. (2010) The angiotensin II type 2 receptor in cardiovascular disease. , J Renin Angiotensin Aldosterone Syst 11(1), 19-31.","DOI":"10.1177\/1470320309347785"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"35.Ross T. (1993) The pathogenesis of atherosclerosis: A perspective for the 1990s. , Nature 362, 801-809.","DOI":"10.1038\/362801a0"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"36.Mendall M A, Patel P, Ballam L, Strachan D, Northfield T C. (1996) C-reactive protein and its relation to cardiovascular risk factors: A population based cross sectional study. , BMJ 312, 1061-1065.","DOI":"10.1136\/bmj.312.7038.1061"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"37.Carpenter L L, Gawuga C E, Tyrka A R, Price L H. (2012) C-reactive protein, early life stress, and wellbeing in healthy adults. , Acta Psychiatr Scand 126(6), 402-410.","DOI":"10.1111\/j.1600-0447.2012.01892.x"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"38.Stanton A. (2003) Potential of renin inhibition in cardiovascular disease. , J Renin Angiotensin Aldosterone Syst 4, 6-10.","DOI":"10.3317\/jraas.2003.008"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"39.Wood J M, Maibaum J, Rahuel J. (2003) Structure-based design of aliskiren, a novel orally effective renin inhibitor. , Biochem Biophys Res Commun 308, 698-705.","DOI":"10.1016\/S0006-291X(03)01451-7"}],"container-title":["Journal of Nephrology Advances"],"link":[{"URL":"https:\/\/openaccesspub.org\/jna\/article\/1650","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T10:13:46Z","timestamp":1627726426000},"score":0.0,"resource":{"primary":{"URL":"https:\/\/openaccesspub.org\/jna\/article\/1650"}},"editor":[{"given":"Sasho","family":"Stoleski","sequence":"additional","affiliation":[{"name":"Institute of Occupational Health of R. Macedonia, WHO CC and Ga2len CC."}],"role":[{"role":"editor","vocabulary":"crossref"}]}],"issued":{"date-parts":[[2021,6,26]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,12,16]]}},"URL":"https:\/\/doi.org\/10.14302\/issn.2574-4488.jna-21-3847","ISSN":["2574-4488"],"issn-type":[{"value":"2574-4488","type":"electronic"}],"published":{"date-parts":[[2021,6,26]]}},{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T14:12:47Z","timestamp":1753884767374,"version":"3.41.2"},"reference-count":22,"publisher":"Open Access Pub","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JNA"],"abstract":"Polycystic kidney disease is an inherited disease that can lead to high blood pressure and kidney failure. In Mexico, 4.5% of patients with kidney failure are carriers of this disease; the liver is another of the organs affected by this disease that can manifest as abdominal pain and a mass effect in the abdominal cavity; we present 2 cases of polycystic kidney and liver disease (mother and child), in addition to describing the clinical manifestations, two different stages of the disease are shown, being a hereditary disease it is suggested that once a case is identified, an abdominal ultrasound is performed to first-degree relatives in search of cystic lesions to indicate preventive measures that help us preserve the overall well-being of the patient.<\/jats:p>","DOI":"10.14302\/issn.2574-4488.jna-21-3887","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T09:42:13Z","timestamp":1627292533000},"page":"23-30","source":"Crossref","is-referenced-by-count":0,"title":["Hepatic Cysts as a Manifestation of Polycystic Kidney Disease (Polycystic Liver Report of 2 Mother-Son Cases)"],"prefix":"10.14302","volume":"1","author":[{"given":"Osnaya-Romero","family":"N","sequence":"first","affiliation":[{"name":"Unidad de investigaci\u00f3n cl\u00ednica Instituto Nacional de Pediatr\u00eda."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conrado","family":"S","sequence":"additional","affiliation":[{"name":"Endocrinologia Hospital 1\u00b0 de octubre Hospital del ISSTE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dautt","family":"P","sequence":"additional","affiliation":[{"name":"Radiologia Hospital ABC."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5410","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"doi-asserted-by":"publisher","unstructured":"1. Panozo Borda SV, Heredia Moy K, Oviedo Gamboa I, Villarroel Arze T, Zegara Santiesteban W, Ricalder Mu\u00f1oz R. Estudio imagenologico de poliquistosis renal autos\u00f3mica dominante, reporte de un caso y revisi\u00f3n de la literatura.Gac.Med. Bol. 2012; 35(1):31-34","key":"ref0","DOI":"10.14201\/gredos.22489"},{"doi-asserted-by":"publisher","unstructured":"2. Ars E, Bernis C, Fraga G, Martinez V, Martins J, Ortiz A, Rodriguez-Perez J C, Sans Laia, Torra R. Gu\u00edas Cl\u00ednicas Espa\u00f1olas de Poliquistosis renal Autos\u00f3mica Dominante 2015. https:\/\/escolasaude.sergas.es\/Docs\/EGSPC\/pilula\/Poliquistosis\/resources\/doc02.pdf","key":"ref1","DOI":"10.14201\/gredos.22489"},{"doi-asserted-by":"publisher","unstructured":"3. M\u00e9ndez-Dur\u00e1n A, M\u00e9ndez-Bueno J F, Tapia-Y\u00e1\u00f1ez T, Mu\u00f1oz Montes A, Aguilar-S\u00e1nchez L. (2010). Epidemiolog\u00eda de la insuficiencia renal cr\u00f3nica en M\u00e9xico.Dial-Trasp. 31(1): 7-11","key":"ref2","DOI":"10.1016\/s1886-2845(10)70004-7"},{"doi-asserted-by":"crossref","unstructured":"4. Harris P C, Torres V E. Polycystic kidney disease. Annu Rev Med. 2009; 60:321-37.","key":"ref3","DOI":"10.1146\/annurev.med.60.101707.125712"},{"doi-asserted-by":"publisher","unstructured":"5. Gradzik M, Niemczyk M, Golebiowski M, Paczek L. Diagnostic Imaging of Autosomal Dominant Polycystic Kidney Disease. Pol J Radiol. 2016; 81: 441-53.","key":"ref4","DOI":"10.12659\/pjr.894482"},{"doi-asserted-by":"publisher","unstructured":"6. Ravine D, Gibson RN, Walker RG, Sheffield LJ, Kincaid-Smith P, Danks DM. (1994). Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet. 343: 824-7","key":"ref5","DOI":"10.1016\/s0140-6736(94)92026-5"},{"doi-asserted-by":"publisher","unstructured":"7. Pei Y, Obaji J, Dupuis A, Paterson AD, Magistroni R, Dicks E, et al. Unified criteria for ultrasonographic diagnosis of ADPKD. Journal of the American Society of Nephrology. JASN. 2009; 20(1):205-12.","key":"ref6","DOI":"10.1681\/asn.2008050507"},{"unstructured":"8. Tobal D. Noboa O. Poliquistosis renal autos\u00f3mica dominante. Necesidad de diagn\u00f3stico y tratamiento oportuno. Rev med Urug. 2014; 30(3):184-192.","key":"ref7"},{"doi-asserted-by":"publisher","unstructured":"9. Pirson Y, Chauveau D, Torres V. (2002). Management of cerebral aneurysms in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 13(1): 269-76.","key":"ref8","DOI":"10.1681\/asn.v131269"},{"doi-asserted-by":"publisher","unstructured":"10. Torres M J, Rodr\u00edguez P\u00e9rez J.C, Hern\u00e1ndez Socorro C.R, Anabitarte Caballero A, V\u00e1zquez C, Fern\u00e1ndez-Burriel M, P\u00e9rez \u2013Borges P. Palop L. Diagn\u00f3stico molecular de la poliquistosis renal autos\u00f3mica dominante en la comunidad aut\u00f3noma de canarias. Nefrolog\u00eda. 2006; 26(1): 666-672","key":"ref9","DOI":"10.14201\/gredos.22489"},{"doi-asserted-by":"publisher","unstructured":"11. Akoh JA. (2015). Current management of autosomal dominant polycystic kidney disease. World J Nephrol. 4(4):468-79","key":"ref10","DOI":"10.5527\/wjn.v4.i4.468"},{"doi-asserted-by":"publisher","unstructured":"12. Igarashi P, Somlo S. (2002). Genetics and pathogenesis of polycystic kidney disease. Journal of the American Society of Nephrology . 13(9):2384-98","key":"ref11","DOI":"10.1097\/01.asn.0000028643.17901.42"},{"doi-asserted-by":"publisher","unstructured":"13. Torres VE, Harris PC, Pirson Y. (2007). Autosomal dominant polycystic kidney disease. The Lancet. 369: 1287-381","key":"ref12","DOI":"10.1016\/s0140-6736(07)60601-1"},{"doi-asserted-by":"publisher","unstructured":"14. Mart\u00ednez Morcillo A, Esteban de la Rosa MA, De Diego Fern\u00e1ndez P, Garc\u00eda Gonz\u00e1lez M, Fern\u00e1ndez Castillo M, Arg\u00fcelles Toledo I et al. Panor\u00e1mica de la poliquistosis renal autos\u00f3mica dominante en una regi\u00f3n del sur de Espa\u00f1a. Nefro 2018; 38(2): 190-196.","key":"ref13","DOI":"10.1016\/j.nefro.2017.07.002"},{"doi-asserted-by":"publisher","unstructured":"15. Hateboer N, Dijk MA, Bogdanova N, Coto E, Saggar-Malik AK, San Millan JL, et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet. 1999;353(9147):103-107","key":"ref14","DOI":"10.1016\/s0140-6736(98)03495-3"},{"unstructured":"16. Fraile G\u00f3mez P, Corral Moro E, Garc\u00eda-Cosmes P, Gonzalez Sarmiento R, Tabernero Romo JM. Genetic analysis (PKD2) of autosomal dominant poliycystic kidney disease. Nefrolog\u00eda. 2009; 29 (6):562-568","key":"ref15"},{"unstructured":"17. Garc\u00eda-Garces M, S\u00e1nchez Zavala J, Mckinney Novelo I, Corrales Rosas B, Zavala Garc\u00eda C, Brisuela Alc\u00e1ntara D, Herrera Bello H, Albores Saavedra J, Gonz\u00e1lez Chon O. Enfermedad poliqu\u00edstica hep\u00e1tica asociada a enfermedad poliq\u00edstica renal autos\u00f3mica dominante. Rev Invest Med Sur. 2011; 18(3): 132-135.","key":"ref16"},{"unstructured":"18. Irazabal M.V, Torres V.E. Poliquistosis renal autos\u00f3mica dominante .Nefrolog\u00eda suplemento extraordinario. 2011; 2(1) :1-33","key":"ref17"},{"doi-asserted-by":"publisher","unstructured":"19. Martinez-Perez, Alberola Soler A, Domingo del Pozo C, Permartin-Comella B, Martinez -Lopez E, Vazquez Tarragon A. Laparoscopic surgery and polycistic liver disease: Clinicopathological features and new trend in management. J Min Access Surg .2016; 12: 265-70.","key":"ref18","DOI":"10.4103\/0972-9941.169976"},{"doi-asserted-by":"publisher","unstructured":"20. van Aerts RMM, van de Laarschot LFM, Banales JM, Drenth JPH. Clinical management of polycystic liver disease. J Hepatol. 2018 Apr;68(4):827-837.","key":"ref19","DOI":"10.1016\/j.jhep.2017.11.024"},{"doi-asserted-by":"publisher","unstructured":"21. Ryu H, Kim H, Park HC, et al. (2017). Total kidney and liver volume is a major risk factor for malnutrition in ambulatory patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 18(1):22.","key":"ref20","DOI":"10.1186\/s12882-016-0434-0"},{"doi-asserted-by":"publisher","unstructured":"22. Rahbari-Oskoui F, Williams Olubunmi, Ch A. Mechanisms and management of hypertension in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2014; Dec; 29(12):2194-2201.","key":"ref21","DOI":"10.1093\/ndt\/gft513"}],"container-title":["Journal of Nephrology Advances"],"link":[{"URL":"https:\/\/openaccesspub.org\/jna\/article\/1665","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T09:42:19Z","timestamp":1627292539000},"score":0.0,"resource":{"primary":{"URL":"https:\/\/openaccesspub.org\/jna\/article\/1665"}},"editor":[{"given":"Sasho","family":"Stoleski","sequence":"additional","affiliation":[{"name":"Institute of Occupational Health of R. Macedonia, WHO CC and Ga2len CC."}],"role":[{"role":"editor","vocabulary":"crossref"}]}],"issued":{"date-parts":[[2021,7,21]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,12,16]]}},"URL":"https:\/\/doi.org\/10.14302\/issn.2574-4488.jna-21-3887","ISSN":["2574-4488"],"issn-type":[{"type":"electronic","value":"2574-4488"}],"published":{"date-parts":[[2021,7,21]]},"article-number":"1665"},{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:27:26Z","timestamp":1782534446874,"version":"3.54.5"},"reference-count":21,"publisher":"Open Access Pub","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"DOI":"10.14302\/issn.2574-4488.jna-15-720","type":"journal-article","created":{"date-parts":[[2017,9,10]],"date-time":"2017-09-10T02:21:28Z","timestamp":1505010088000},"page":"48-57","source":"Crossref","is-referenced-by-count":3,"title":["Bedside Lung Ultrasound in the Assessment of Volume Status in Chronic Hemodialysis Patients"],"prefix":"10.14302","volume":"1","author":[{"given":"El Bardai","family":"Ghita","sequence":"first","affiliation":[{"name":"1 Nephrology department, Hassan II University Hospital, Fez, Morocco."},{"name":"* Corresponding author"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dami","family":"Fadoua","sequence":"additional","affiliation":[{"name":"1 Nephrology department, Hassan II University Hospital, Fez, Morocco."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanin","family":"Hakim","sequence":"additional","affiliation":[{"name":"2 Al Ghassani hemodialysis center, Fez, Morocco."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kabbali","family":"Nadia","sequence":"additional","affiliation":[{"name":"1 Nephrology department, Hassan II University Hospital, Fez, Morocco."},{"name":"3 R.E.I.N \u00abRenal Exploration & Investigations in Nephrology \u00bb, molecular basis and bioactive molecules laboratory, Faculty of Medicine and Pharmacy, Sidi Mohamed Ben Abdellah University, Fez, Morocco."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arrayhani","family":"Mohamed","sequence":"additional","affiliation":[{"name":"1 Nephrology department, Hassan II University Hospital, Fez, Morocco."},{"name":"3 R.E.I.N \u00abRenal Exploration & Investigations in Nephrology \u00bb, molecular basis and bioactive molecules laboratory, Faculty of Medicine and Pharmacy, Sidi Mohamed Ben Abdellah University, Fez, Morocco."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sqalli Houssaini","family":"Tarik","sequence":"additional","affiliation":[{"name":"1 Nephrology department, Hassan II University Hospital, Fez, Morocco."},{"name":"3 R.E.I.N \u00abRenal Exploration & Investigations in Nephrology \u00bb, molecular basis and bioactive molecules laboratory, Faculty of Medicine and Pharmacy, Sidi Mohamed Ben Abdellah University, Fez, Morocco."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5410","published-online":{"date-parts":[[2016]]},"reference":[{"key":"ref001","doi-asserted-by":"crossref","unstructured":"1. Seibert E Levin N W Kuhlmann M K Zhu F Bioimpedance, dry weight and blood pressure control: new methods and consequences. Curr Opin Nephrol Hypertens 2005 14 6 543 549","DOI":"10.1097\/01.mnh.0000185983.48319.00"},{"key":"ref002","doi-asserted-by":"crossref","unstructured":"2. Ozkahya M Ok E Toz H Asci G Duman S Basci A Kose T DorhoutMees E J Long-term survival rates in haemodialysis patients treated with strict volume control.Nephrol Dial Transplant 2006 21 12 3506 3513","DOI":"10.1093\/ndt\/gfl487"},{"key":"ref003","doi-asserted-by":"crossref","unstructured":"3. Parfrey P S Foley R N Harnett J D Kent G M Murray D C Barre P E Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 1996 11 1277 1285","DOI":"10.1093\/oxfordjournals.ndt.a027540"},{"key":"ref004","doi-asserted-by":"crossref","unstructured":"4. Zoccali C Benedetto F A Mallamaci F Prognostic value of echocardiographic indicators of left ventricular systolic function in asymptomatic dialysis patients 2004 J Am Soc Nephrol 15 1029 37","DOI":"10.1097\/01.ASN.0000117977.14912.91"},{"key":"ref005","doi-asserted-by":"crossref","unstructured":"5. Picano E Frassi F Agricola E Gligorova S Gargani L Mottola G Ultrasound lung comets: a clinically useful sign of extravascular lung water 2006 J Am Soc Echocardiogr 19 356 363","DOI":"10.1016\/j.echo.2005.05.019"},{"key":"ref006","doi-asserted-by":"crossref","unstructured":"6. Lichtenstein D M\u00e9zi\u00e8re G Biderman P The comet-tail artifact. An ultrasound sign of alveolar-interstitial syndrome 1997 Am J Respir Crit Care Med 156 5 1640 1646","DOI":"10.1164\/ajrccm.156.5.96-07096"},{"key":"ref007","doi-asserted-by":"crossref","unstructured":"7. Dexheimer L Dalcin P Teixeira C Beltrami F Lung ultrasound in critically ill patients: a new diagnostic tool 2012 J Bras Pneumol 38 246 56","DOI":"10.1590\/S1806-37132012000200015"},{"key":"ref008","doi-asserted-by":"crossref","unstructured":"8. Picano E Gargani L Gheorghiade M Why when, and how to assess pulmonary congestion in heart failure: pathophysiological, clinical, and methodological implications. Heart Fail Rev 2010 15 63 72","DOI":"10.1007\/s10741-009-9148-8"},{"key":"ref009","doi-asserted-by":"crossref","unstructured":"9. Frassi F Gargani L Tesorio P Raciti M Mottola G PicanoE Prognostic value of extravascular lung water assessed with ultrasound lung comets by chest sonography in patients with dyspnea and\/or chest pain.JCardFail 2007 13 10 830 835","DOI":"10.1016\/j.cardfail.2007.07.003"},{"key":"ref010","doi-asserted-by":"crossref","unstructured":"10. Mallamaci F Benedetto F A Tripepi R Rastelli S Castellino P Tripepi G Picano E Zoccali C Detection of pulmonary congestion by chest ultrasound in dialysis patients. JACC Cardiovasc Imaging 2010 3 6 586 594","DOI":"10.1016\/j.jcmg.2010.02.005"},{"key":"ref011","doi-asserted-by":"crossref","unstructured":"11. Machek P Jirka T Moissl U Chamney P Wabel P Guided optimization of fluid status in haemodialysis patients 2010 Nephrol Dial Transplant 25 2 538 544","DOI":"10.1093\/ndt\/gfp487"},{"key":"ref012","doi-asserted-by":"crossref","unstructured":"12. Brennan J M Ronan A Goonewardena S Blair J E Hammes M Shah D Vasaiwala S Kirkpatrick J N Spencer K T Handcarried ultrasound measurement of the inferior vena cava for assessment of intravascular volume status in the outpatient hemodialysis clinic. Clin J Am SocNephrol 2006 1 4 749 753","DOI":"10.2215\/CJN.00310106"},{"key":"ref013","doi-asserted-by":"crossref","unstructured":"13. Volpicelli G Mussa A Garofalo G Cardinale L Casoli G Perotto F Fava C Frascisco M Bedside lung ultrasound in the assessment of alveolar-interstitial syndrome 2006 Am J Emerg Med 24 6 689 696","DOI":"10.1016\/j.ajem.2006.02.013"},{"key":"ref014","doi-asserted-by":"crossref","unstructured":"14. Basso F Milan Manani S Cruz D N Teixeira C Brendolan A Nalesso F Zanella M Ronco C Comparison and Reproducibility of Techniques for Fluid Status Assessment in Chronic Hemodialysis Patients. Cardiorenal Med 2013 3 2 104 112","DOI":"10.1159\/000351008"},{"key":"ref015","doi-asserted-by":"crossref","unstructured":"15. Peacock W F Soto K M Current techniques of fluid status assessment 2010 ContribNephrol 164 128 142","DOI":"10.1159\/000313726"},{"key":"ref016","doi-asserted-by":"crossref","unstructured":"16. Di Iorio BR Scalfi L Terracciano V Bellizzi V A systematic evaluation of bioelectrical impedance measurement after hemodialysis session. Kidney Int 2004 65 6 2435 2440","DOI":"10.1111\/j.1523-1755.2004.00660.x"},{"key":"ref017","doi-asserted-by":"crossref","unstructured":"17. Agarwal R Bouldin J M Light R P Garg A Inferior vena cavadiameter and left atrial diameter measure volume but not dry weight 2011 Clin J Am SocNephrol 6 5 1066 1072","DOI":"10.2215\/CJN.09321010"},{"key":"ref018","doi-asserted-by":"crossref","unstructured":"18. Trezzi M Torzillo D Ceriani E Costantino G Caruso S Damavandi P T Genderini A Cicardi M Montano N Cogliati C Lung ultrasonography for the assessment of rapid extravascular water variation: evidence from hemodialysis patients 2013 Intern Emerg Med 8 5 409 415","DOI":"10.1007\/s11739-011-0625-4"},{"key":"ref019","doi-asserted-by":"crossref","unstructured":"19. N Dugo M Vitturi M Simoni F Soattin L Zagatti R Maresca Maresca M C Lung ultrasound during hemodialysis: the role in the assessment of volume status. Int Urol Nephrol 2014 46 169 174","DOI":"10.1007\/s11255-013-0500-5"},{"key":"ref020","doi-asserted-by":"crossref","unstructured":"20. Noble V E Murray A F Capp R Sylvia-Reardon M H Steele D J Liteplo A Ultrasound assessment for extravascular lung water in patients undergoing hemodialysis. Time course for resolution 2009 Chest 135 1433 1439","DOI":"10.1378\/chest.08-1811"},{"key":"ref021","doi-asserted-by":"crossref","unstructured":"21. Kalantar-Zadeh K Regidor D L Kovesdy C P D Van Wyck Bunnapradist S Horwich T B Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis 2009 Circulation 119 671 679","DOI":"10.1161\/CIRCULATIONAHA.108.807362"}],"container-title":["Journal Of Nephrology Advances"],"language":"en","link":[{"URL":"https:\/\/openaccesspub.org\/article\/282\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openaccesspub.org\/article\/282\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T11:55:08Z","timestamp":1760702108000},"score":0.0,"resource":{"primary":{"URL":"https:\/\/openaccesspub.org\/nephrology-advances\/article\/282"}},"issued":{"date-parts":[[2016]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.14302\/issn.2574-4488.jna-15-720","ISSN":["2574-4488"],"issn-type":[{"value":"2574-4488","type":"electronic"}],"published":{"date-parts":[[2016]]}},{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T20:54:51Z","timestamp":1648760091106},"reference-count":0,"publisher":"Open Access Pub","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JNA"],"DOI":"10.14302\/issn.2574-4488.jna-14-614","type":"journal-article","created":{"date-parts":[[2017,9,10]],"date-time":"2017-09-10T06:21:28Z","timestamp":1505024488000},"page":"1-5","source":"Crossref","is-referenced-by-count":2,"title":["REFRACTORY ANAEMIA WITH HYPEROXALUREA"],"prefix":"10.14302","volume":"1","author":[{"given":"Ayesha","family":"Ehsan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayaz","family":"Lone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omer","family":"Sabir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nauman","family":"Tareef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabiha","family":"Riaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imrana","family":"Tanvir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5410","published-online":{"date-parts":[[2015,5,19]]},"container-title":["Journal Of Nephrology Advances"],"deposited":{"date-parts":[[2017,9,10]],"date-time":"2017-09-10T06:21:29Z","timestamp":1505024489000},"score":0.0,"resource":{"primary":{"URL":"http:\/\/openaccesspub.org\/jna\/article\/153"}},"editor":[{"given":"Ying-Yong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"issued":{"date-parts":[[2015,5,19]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,5,19]]}},"URL":"https:\/\/doi.org\/10.14302\/issn.2574-4488.jna-14-614","ISSN":["2574-4488"],"issn-type":[{"value":"2574-4488","type":"electronic"}],"published":{"date-parts":[[2015,5,19]]}},{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T17:31:31Z","timestamp":1769016691097,"version":"3.49.0"},"reference-count":0,"publisher":"Open Access Pub","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JNA"],"DOI":"10.14302\/issn.2574-4488.jna-16-1008","type":"journal-article","created":{"date-parts":[[2017,9,10]],"date-time":"2017-09-10T02:21:28Z","timestamp":1505010088000},"page":"58-62","source":"Crossref","is-referenced-by-count":2,"title":["Reduction in Estimated Glomerular Filtration Rate in Patients with Elevated Blood Urea Nitrogen but Normal for any Other Markers of Kidney Damage"],"prefix":"10.14302","volume":"1","author":[{"given":"Xu","family":"Xiaoyong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su","family":"Jianrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diao","family":"Zongli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5410","published-online":{"date-parts":[[2017,6,17]]},"container-title":["Journal Of Nephrology Advances"],"deposited":{"date-parts":[[2017,9,10]],"date-time":"2017-09-10T02:21:32Z","timestamp":1505010092000},"score":0.0,"resource":{"primary":{"URL":"http:\/\/openaccesspub.org\/jna\/article\/299"}},"editor":[{"given":"Ying-Yong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"issued":{"date-parts":[[2017,6,17]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,5,19]]}},"URL":"https:\/\/doi.org\/10.14302\/issn.2574-4488.jna-16-1008","ISSN":["2574-4488"],"issn-type":[{"value":"2574-4488","type":"electronic"}],"published":{"date-parts":[[2017,6,17]]}},{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:24:57Z","timestamp":1760217897276,"version":"3.41.2"},"reference-count":112,"publisher":"Open Access Pub","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JNA"],"abstract":"Renal fibrosis was a chronic and progressive process affecting kidneys in chronic kidney disease (CKD), regardless of cause. Although no effective targeted therapy yet existed to retard renal fibrosis, a number of important recent advances have highlighted the cellular and molecular mechanisms underlying the renal fibrosis. The advances including TGF-\u03b2\/Smad pathway, oxidative stress and inflammation, hypoxia and gut microbiota-derived from uremic solutes were highlighted that could provide therapeutic targets. New therapeutic targets and strategies that are particularly promising for development of new treatments for patients with CKD were also highlighted.<\/jats:p>","DOI":"10.14302\/issn.2574-4488.jna-18-2443","type":"journal-article","created":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T06:47:28Z","timestamp":1542091648000},"page":"4-14","source":"Crossref","is-referenced-by-count":15,"title":["Action Mechanisms and Therapeutic Targets of Renal Fibrosis"],"prefix":"10.14302","volume":"1","author":[{"given":"Shi-Xing","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Nephrology, Baoji Central Hospital, No. 8 Jiangtan Road, Baoji, Shaanxi 721008, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You-Quan","family":"Shang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Baoji Central Hospital, No. 8 Jiangtan Road, Baoji, Shaanxi 721008, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan-Qiao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Baoji Central Hospital, No. 8 Jiangtan Road, Baoji, Shaanxi 721008, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Baoji Central Hospital, No. 8 Jiangtan Road, Baoji, Shaanxi 721008, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5410","published-online":{"date-parts":[[2018,11,12]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1.Webster A C, Nagler E V, Morton R L, Masson P. (2017) Chronic kidney disease. Lancet. 389-1238.","DOI":"10.1016\/s0140-6736(16)32064-5"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2.Hocher B, Adamski J. (2017) Metabolomics for clinical use and research in chronic kidney disease. Nat Rev Nephrol. 13, 269-284.","DOI":"10.1038\/nrneph.2017.30"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.Zhang L, Long J, Jiang W.Trends in chronic kidney disease in China. The New England journal of medicine 2016;. 375-905.","DOI":"10.1056\/NEJMc1602469"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4.Stevens L A, Coresh J, Greene T, Levey A S. (2006) Assessing kidney function--measured and estimated glomerular filtration rate. The New England journal of medicine. 354-2473.","DOI":"10.1056\/nejmra054415"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5.Wynn T A. (2012) Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nature medicine. 18, 1028-1040.","DOI":"10.1038\/nm.2807"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6.Meng X M, PMK Tang, Li J, Lan H Y. (2015) TGF-\u03b2\/Smad signaling in renal fibrosis. Front Physiol. 6-82.","DOI":"10.3389\/fphys.2015.00082"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7.Lan H Y. (2011) Diverse roles of TGF-beta\/Smads in renal fibrosis and inflammation. International journal of biological sciences. 7, 1056-1067.","DOI":"10.7150\/ijbs.7.1056"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8.Loboda A, Sobczak M, Jozkowicz A, Dulak J. (2016) TGF-beta1\/Smads and miR-21 in renal fibrosis and inflammation. Mediators of inflammation. 8319283.","DOI":"10.1155\/2016\/8319283"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9.Higgins S P, Tang Y, Higgins C E. (2018) TGF-beta1\/p53 signaling in renal fibrogenesis. Cellular signalling. 43, 1-10.","DOI":"10.1016\/j.cellsig.2017.11.005"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.Hu H H, Chen D Q, Wang Y N. (2018) New insights into TGF-\u03b2\/Smad signaling in tissue fibrosis. Chem Biol Interact. 292-76.","DOI":"10.1016\/j.cbi.2018.07.008"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11.Afandi B, Bernieh B.Acute bilateral hydro nephrosis after the use of dapagliflozin. , Journal of Nephrology Advances 2015, 42-47.","DOI":"10.14302\/issn.2574-4488.jna-15-712"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12.Andreucci M, Faga T, G De Sarro, Michael A.The toxicity of iodinated radiographic contrast agents in the clinical practice. , Journal of Nephrology Advances 2015, 6-41.","DOI":"10.14302\/issn.2574-4488.jna-14-601"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13.Ehsan A, Lone A, Sabir O, Tareef N, Riaz S.Tanvir I. Refractory anaemia with hyperoxalurea. , Journal of Nephrology Advances 2015, 1-5.","DOI":"10.14302\/issn.2574-4488.jna-14-614"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14.Soni S S, Barnela S R, Saboo S S, Deshpande A V, Deshmukh S S.Takalkar UV. Arteriovenous Fistula in A Patient with Aberrant Radial Artery. , Journal of Nephrology Advances 2016, 1-3.","DOI":"10.14302\/issn.2574-4488.jna-16-1225"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15.G E B, Dami F, Hanin H, Kabbali N, Arrayhani M et al.Bedside lung ultrasound in the assessment of volume status in chronic hemodialysis patients. , Journal of Nephrology Advances 2015, 48-57.","DOI":"10.14302\/issn.2574-4488.jna-15-720"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16.Edeling M, Ragi G, Huang S, Pavenstadt H, Susztak K. (2016) Developmental signalling pathways in renal fibrosis: the roles of Notch, Wnt and Hedgehog. Nat Rev Nephrol. 12, 426-439.","DOI":"10.1038\/nrneph.2016.54"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17.Kok H M, Falke L L, Goldschmeding R, Nguyen T Q. (2014) Targeting CTGF, EGF and PDGF pathways to prevent progression of kidney disease. Nat Rev Nephrol. 10, 700-711.","DOI":"10.1038\/nrneph.2014.184"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18.Meng X M, Nikolic-Paterson D J, Lan H Y. (2016) TGF-\u03b2: the master regulator of fibrosis. , Nat Rev Nephrol 12, 325-338.","DOI":"10.1038\/nrneph.2016.48"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19.Yaswen L, Kulkarni A B, Fredrickson T. (1996) Autoimmune manifestations in the transforming growth factor-\u03b21 knockout mouse. Blood. 87, 1439-1445.","DOI":"10.1182\/blood.V87.4.1439.bloodjournal8741439"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20.Li M O, Sanjabi S, Flavell R A. (2006) Transforming growth factor-\u03b2 controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity. 25, 455-471.","DOI":"10.1016\/j.immuni.2006.07.011"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21.Li M O, Wan Y Y, Flavell R A. (2007) T cell-produced transforming growth factor-\u03b21 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity. 26, 579-591.","DOI":"10.1016\/j.immuni.2007.03.014"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22.Huang X R, Chung A C, Wang X J, Lai K N, Lan H Y. (2008) Mice overexpressing latent TGF-\u03b21 are protected against renal fibrosis in obstructive kidney disease. American journal of physiology Renal physiology. 295-118.","DOI":"10.1152\/ajprenal.00021.2008"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23.Huang X R, Chung A C, Zhou L, Wang X J, Lan H Y. (2008) Latent TGF-\u03b21 protects against crescentic glomerulonephritis. , Journal of the American Society of Nephrology : JASN 19, 233-242.","DOI":"10.1681\/asn.2007040484"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24.Budi E H, Duan D, Derynck R. (2017) Transforming Growth Factor-\u03b2 Receptors and Smads: Regulatory Complexity and Functional Versatility. Trends in cell biology. 27, 658-672.","DOI":"10.1016\/j.tcb.2017.04.005"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25.Sureshbabu A, Muhsin S A, Choi M E.TGF-\u03b2 signaling in the kidney: profibrotic and protective effects. American journal of physiology Renal physiology 2016; 310:. 596-606.","DOI":"10.1152\/ajprenal.00365.2015"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26.Lan H Y. (2011) Diverse roles of TGF-\u03b2\/Smads in renal fibrosis and inflammation. International journal of biological sciences. 7, 1056-1067.","DOI":"10.7150\/ijbs.7.1056"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27.Vanhove T, Goldschmeding R, Kuypers D. (2017) Kidney fibrosis: origins and interventions. Transplantation. 101, 713-726.","DOI":"10.1097\/tp.0000000000001608"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28.Shi Y, Massague J. (2003) Mechanisms of TGF-\u03b2 signaling from cell membrane to the nucleus. Cell. 113-685.","DOI":"10.1016\/s0092-8674(03)00432-x"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29.Sharma K. (2011) Obesity, oxidative stress, and fibrosis in chronic kidney disease. Kidney Int Suppl. 4, 113-117.","DOI":"10.1038\/kisup.2014.21"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30.Sharma K, McGowan T A. (2000) TGF-\u03b2 in diabetic kidney disease: role of novel signaling pathways. Cytokine & growth factor reviews. 11, 115-123.","DOI":"10.1016\/s1359-6101(99)00035-0"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31.Liu Z, Huang X R, Chen H Y, Fung E, Liu J et al. (1979) Deletion of angiotensin-converting enzyme-2 promotes hypertensive nephropathy by targeting Smad7 for ubiquitin degradation. Hypertension (Dallas, Tex :. 70, 822-830.","DOI":"10.1161\/hypertensionaha.117.09600"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32.Nogueira A, Pires M J, Oliveira P A. (2017) Pathophysiological mechanisms of renal fibrosis: A review of animal models and therapeutic strategies. In vivo (Athens. , Greece 31, 1-22.","DOI":"10.21873\/invivo.11019"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33.Wang W, Huang X R, Canlas E. (2006) Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circulation research. 98, 1032-1039.","DOI":"10.1161\/01.res.0000218782.52610.dc"},{"key":"ref33","unstructured":"34.Liu G X, Li Y Q, Huang X R. (1979) Smad7 inhibits AngII-mediated hypertensive nephropathy in a mouse model of hypertension. Clinical science (London. , England : 127-195."},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"35.Zhou B, Mu J, Gong Y. (2017) Brd4 inhibition attenuates unilateral ureteral obstruction-induced fibrosis by blocking TGF-\u03b2-mediated Nox4 expression. Redox biology. 11, 390-402.","DOI":"10.1016\/j.redox.2016.12.031"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"36.Yang F, Huang X R, Chung A C, Hou C C, Lai K N et al.Essential role for Smad3 in angiotensin II-induced tubular epithelial-mesenchymal transition. The Journal of pathology 2010;. 221-390.","DOI":"10.1002\/path.2721"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"37.Huang X Z, Wen D, Zhang M. (2014) Sirt1 activation ameliorates renal fibrosis by inhibiting the TGF-\u03b2\/Smad3 pathway. Journal of cellular biochemistry. 115-996.","DOI":"10.1002\/jcb.24748"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"38.Wang Y Y, Jiang H, Pan J. (2017) Macrophage-to-myofibroblast transition contributes to interstitial fibrosis in chronic renal allograft Injury. , Journal of the American Society of Nephrology : JASN 28, 2053-2067.","DOI":"10.1681\/asn.2016050573"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"39.Chung A C, Zhang H, Kong Y Z. (2010) Advanced glycation end-products induce tubular CTGF via TGF-\u03b2-independent Smad3 signaling. , Journal of the American Society of Nephrology : JASN 21, 249-260.","DOI":"10.1681\/asn.2009010018"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"40.Chen H Y, Huang X R, Wang W. (2011) The protective role of Smad7 in diabetic kidney disease: mechanism and therapeutic potential. Diabetes. 60, 590-601.","DOI":"10.2337\/db10-0403"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"41.Al-Rasheed N M, Al-Rasheed N M, Al-Amin M A. (2016) Fenofibrate attenuates diabetic nephropathy in experimental diabetic rat's model via suppression of augmented TGF-\u03b21\/Smad3 signaling pathway. Archives of physiology and biochemistry. 122-186.","DOI":"10.3109\/13813455.2016.1164186"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"42.Zhou L, Fu P, Huang X R. (2010) Mechanism of chronic aristolochic acid nephropathy: role of Smad3. American journal of physiology Renal physiology. 298-1006.","DOI":"10.1152\/ajprenal.00675.2009"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"43.Verrecchia F, Chu M L, Mauviel A. (2001) Identification of novel TGF-\u03b2 \/Smad gene targets in dermal fibroblasts using a combined cDNA microarray\/promoter transactivation approach. The Journal of biological chemistry. 276-17058.","DOI":"10.1074\/jbc.m100754200"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"44.Chen D Q, Feng Y L, Cao G, Zhao Y Y. (2018) Natural products as a source for antifibrosis therapy. Trends in pharmacological sciences. 39, 937-952.","DOI":"10.1016\/j.tips.2018.09.002"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"45.Chen D Q, Hu H H, Wang Y N, Feng Y L, Cao G et al. (2018) Natural products for the prevention and treatment of kidney disease. Phytomedicine. 50, 50-60.","DOI":"10.1016\/j.phymed.2018.09.182"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"46.Davis F M, Stewart T A, Thompson E W, Monteith G R. (2014) Targeting EMT in cancer: opportunities for pharmacological intervention. Trends in pharmacological sciences. 35, 479-488.","DOI":"10.1016\/j.tips.2014.06.006"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"47.Jiang W Y. (2005) Therapeutic wisdom in traditional Chinese medicine: a perspective from modern science. Trends in pharmacological sciences. 26, 558-563.","DOI":"10.1016\/j.tips.2005.09.006"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"48.Zhang Z H, Li M H, Liu D. (2018) Rhubarb protect against tubulointerstitial fibrosis by inhibiting TGF-\u03b2\/Smad pathway and improving abnormal metabolome in chronic kidney disease. Front Pharmacol. 9.","DOI":"10.3389\/fphar.2018.01029"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"49.Dou F, Miao H, Wang J W. (2018) An integrated lipidomics and phenotype study reveals protective effect and biochemical mechanism of traditionally used Alisma orientale Juzepzuk in chronic renal disease. Front Pharmacol. 9-53.","DOI":"10.3389\/fphar.2018.00053"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"50.Zhang Z H, Vaziri N D, Wei F, Cheng X L, Bai X et al. (2016) An integrated lipidomics and metabolomics reveal nephroprotective effect and biochemical mechanism of Rheum officinale in chronic renal failure. Sci Rep. 6, 22151.","DOI":"10.1038\/srep22151"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"51.Zhang Z H, Wei F, Vaziri N D. (2015) Metabolomics insights into chronic kidney disease and modulatory effect of rhubarb against tubulointerstitial fibrosis. Sci Rep. 5, 14472.","DOI":"10.1038\/srep14472"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"52.Chen H, Yang T, Wang M C, Chen D Q, Yang Y et al. (2018) Novel RAS inhibitor 25-O-methylalisol F attenuates epithelial-to-mesenchymal transition and tubulo-interstitial fibrosis by selectively inhibiting TGF-\u03b2-mediated Smad3 phosphorylation. Phytomedicine. 42, 207-218.","DOI":"10.1016\/j.phymed.2018.03.034"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"53.Wang M, Chen D Q, Wang M C. (2017) Poricoic acid ZA, a novel RAS inhibitor, attenuates tubulo-interstitial fibrosis and podocyte injury by inhibiting TGF-\u03b2\/Smad signaling pathway. Phytomedicine. 36, 243-253.","DOI":"10.1016\/j.phymed.2017.10.008"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"54.Wang M, Chen D Q, Chen L. (2018) Novel RAS inhibitors poricoic acid ZG and poricoic acid ZH attenuate renal fibrosis via Wnt\/\u03b2-catenin pathway and targeted phosphorylation of smad3 signaling. Journal of agricultural and food chemistry. 66, 1828-1842.","DOI":"10.1021\/acs.jafc.8b00099"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"55.Zhao Y Y, Zhang L, Long F Y. (2013) UPLC-Q-TOF\/HSMS\/MS(E)-based metabonomics for adenine-induced changes in metabolic profiles of rat faeces and intervention effects of ergosta-4,6,8(14),22-tetraen-3-one. Chem Biol Interact. 201-31.","DOI":"10.1016\/j.cbi.2012.12.002"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"56.Chen L, Chen D Q, Wang M. (2017) Role of RAS\/Wnt\/ \u03b2-catenin axis activation in the pathogenesis of podocyte injury and tubulo-interstitial nephropathy. Chem Biol Interact. 273-56.","DOI":"10.1016\/j.cbi.2017.05.025"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"57.Wang M, Chen D Q, Chen L. (2018) Novel inhibitors of the cellular renin-angiotensin system components, poricoic acids, target Smad3 phosphorylation and Wnt\/beta-catenin pathway against renal fibrosis. , Br J Pharmacol 175-2689.","DOI":"10.1111\/bph.14333"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"58.Ai J, Nie J, He J. (2015) GQ5 hinders renal fibrosis in obstructive nephropathy by selectively inhibiting TGF-\u03b2-induced Smad3 phosphorylation. , J Am Soc Nephrol 26, 1827-1838.","DOI":"10.1681\/asn.2014040363"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"59.Sun X, Liu Y, Li C. (2017) Recent advances of Curcumin in the prevention and treatment of renal fibrosis. BioMed research international. 2418671.","DOI":"10.1155\/2017\/2418671"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"60.Zhou X, Zhang J, Xu C, Wang W. (2014) Curcumin ameliorates renal fibrosis by inhibiting local fibroblast proliferation and extracellular matrix deposition. Journal of pharmacological sciences. 126-344.","DOI":"10.1254\/jphs.14173fp"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"61.Li A, Zhang X, Shu M. (2017) Arctigenin suppresses renal interstitial fibrosis in a rat model of obstructive nephropathy. Phytomedicine : international journal of phytotherapy and phytopharmacology. 30, 28-41.","DOI":"10.1016\/j.phymed.2017.03.003"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"62.Chen C L, Chen Y H, Tai M C, Liang C M, Lu D W et al. (2017) Resveratrol inhibits transforming growth factor-\u03b22-induced epithelial-to-mesenchymal transition in human retinal pigment epithelial cells by suppressing the Smad pathway. Drug Des Devel Ther. 11, 163-173.","DOI":"10.2147\/dddt.s126743"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"63.Qin T, Yin S, Yang J.Sinomenine attenuates renal fibrosis through Nrf2-mediated inhibition of oxidative stress and TGF\u03b2 signaling. Toxicology and applied pharmacology 2016;. 304-1.","DOI":"10.1016\/j.taap.2016.05.009"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"64.Zhang X, He H, Liang D. (2016) Protective effects of Berberine on renal injury in streptozotocin (STZ)-induced diabetic mice. International journal of molecular sciences. 17.","DOI":"10.3390\/ijms17081327"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"65.Wang F M, Yang Y J, Ma L L, Tian X J, He Y Q. (2014) Berberine ameliorates renal interstitial fibrosis induced by unilateral ureteral obstruction in rats. Nephrology. , (Carlton, Vic) 19, 542-551.","DOI":"10.1111\/nep.12271"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"66.Cheng H, Bo Y, Shen W. (2015) Leonurine ameliorates kidney fibrosis via suppressing TGF-\u03b2 and NF-kappaB signaling pathway. in UUO mice. International immunopharmacology 25, 406-415.","DOI":"10.1016\/j.intimp.2015.02.023"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"67.Wang B, Liu D, Zhu Q H. (2016) Rutin ameliorates kidney interstitial fibrosis in rats with obstructive nephropathy. International immunopharmacology. 35, 77-84.","DOI":"10.1016\/j.intimp.2016.03.029"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"68.Yang J, Kan M, Wu G Y. (2016) Bergenin ameliorates diabetic nephropathy in rats via suppressing renal inflammation and TGF-\u03b21-Smads pathway. Immunopharmacology and immunotoxicology. 38, 145-152.","DOI":"10.3109\/08923973.2016.1142560"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"69.Wang H W, Shi L, Xu Y P, Qin X Y, Wang Q Z. (2016) Oxymatrine inhibits renal fibrosis of obstructive nephropathy by downregulating the TGF-\u03b21-Smad3 pathway. Renal failure. 38, 945-951.","DOI":"10.3109\/0886022x.2016.1164185"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"70.Liu L, Wang Y, Yan R. (2016) Oxymatrine inhibits renal tubular EMT induced by high glucose via upregulation of SnoN and inhibition of TGF-\u03b21\/Smad signaling pathway. PloS one. 11, 0151986.","DOI":"10.1371\/journal.pone.0151986"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"71.Lee E S, Kim H M, Kang J S. (2016) Oleanolic acid and N-acetylcysteine ameliorate diabetic nephropathy through reduction of oxidative stress and endoplasmic reticulum stress in a type 2 diabetic rat model. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 31, 391-400.","DOI":"10.1093\/ndt\/gfv377"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"72.Wang D T, Huang R H, Cheng X, Zhang Z H, Yang Y J et al. (2015) Tanshinone IIA attenuates renal fibrosis and inflammation via altering expression of TGF-\u03b2\/Smad and NF-kappaB signaling pathway in 5\/6 nephrectomized rats. International immunopharmacology. 26, 4-12.","DOI":"10.1016\/j.intimp.2015.02.027"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"73.Zhang L, Li Z, He W. (2015) Effects of Astragaloside IV against the TGF-\u03b21-induced epithelial-to-mesenchymal transition in peritoneal mesothelial cells by promoting Smad 7 expression. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 37, 43-54.","DOI":"10.1159\/000430332"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"74.Wang L, Chi Y F, Yuan Z T. (2014) Astragaloside IV inhibits renal tubulointerstitial fibrosis by blocking TGF-\u03b2\/Smad signaling pathway in vivo and in vitro. Experimental biology and medicine. , (Maywood, NJ) 239-1310.","DOI":"10.1177\/1535370214532597"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"75.Luo Q, Tian L, L Di. (2015) (+\/-)-Sinensilactam A, a pair of rare hybrid metabolites with Smad3 phosphorylation inhibition from Ganoderma sinensis. Organic letters. 17, 1565-1568.","DOI":"10.1021\/acs.orglett.5b00448"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"76.Yin J, Liao S X, He Y. (2015) Dysbiosis of gut microbiota with reduced trimethylamine-N-oxide level in patients with large-artery atherosclerotic stroke or transient ischemic attack. , Journal of the American Heart Association 4.","DOI":"10.1161\/jaha.115.002699"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"77.Chen H, Cao G, Chen D Q. (2016) Metabolomics insights into activated redox signaling and lipid metabolism dysfunction in chronic kidney disease progression. Redox Biol. 10, 168-178.","DOI":"10.1016\/j.redox.2016.09.014"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"78.Kansanen E, Kuosmanen S M, Leinonen H, Levonen A L. (2013) The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer. Redox Biol. 1, 45-49.","DOI":"10.1016\/j.redox.2012.10.001"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"79.Milkovic L, Zarkovic N, Saso L. (2017) Controversy about pharmacological modulation of Nrf2 for cancer therapy. Redox Biol. 12, 727-732.","DOI":"10.1016\/j.redox.2017.04.013"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"80.Chen D Q, Cao G, Chen H. (2017) Gene and protein expressions and metabolomics exhibit activated redox signaling and wnt\/\u03b2-catenin pathway are associated with metabolite dysfunction in patients with chronic kidney disease. Redox Biol. 12, 505-521.","DOI":"10.1016\/j.redox.2017.03.017"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"81.Ruiz S, Pergola P E, Zager R A, Vaziri N D. (2013) Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int. 83, 1029-1041.","DOI":"10.1038\/ki.2012.439"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"82.Machowska A, Carrero J J, Lindholm B, Stenvinkel P. (2016) Therapeutics targeting persistent inflammation in chronic kidney disease. Translational research : the journal of laboratory and clinical medicine. 167-204.","DOI":"10.1016\/j.trsl.2015.06.012"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"83.Zhao Y Y, Cheng X L, Wei F. (2012) Serum metabonomics study of adenine-induced chronic renal failure in rats by ultra performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. Biomarkers. 17, 48-55.","DOI":"10.3109\/1354750x.2011.637180"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"84.Zhao Y Y, Cheng X L, Wei F. (2013) Intrarenal metabolomic investigation of chronic kidney disease and its TGF-\u03b21 mechanism in induced-adenine rats using UPLC Q-TOF\/HSMS\/MS(E). , J Proteome Res 12, 2692-2703.","DOI":"10.1021\/pr3007792"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"85.Zhao Y Y, Wang H L, Cheng X L. (2015) Metabolomics analysis reveals the association between lipid abnormalities and oxidative stress, inflammation, fibrosis, and Nrf2 dysfunction in aristolochic acid-induced nephropathy. Sci Rep. 5, 12936.","DOI":"10.1038\/srep12936"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"86.Trujillo J, Chirino Y I, Molina-Jijon E, Anderica-Romero A C, Tapia E et al. (2013) Renoprotective effect of the antioxidant curcumin: Recent findings. Redox Biol. 1, 448-456.","DOI":"10.1016\/j.redox.2013.09.003"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"87.Humphreys B D. (2018) Mechanisms of Renal Fibrosis. Annual Review of Physiology. 80, 309-326.","DOI":"10.1146\/annurev-physiol-022516-034227"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"88.Meng X M, Nikolic-Paterson D J, Lan H Y. (2014) Inflammatory processes in renal fibrosis. Nat Rev Nephrol. 10, 493-503.","DOI":"10.1038\/nrneph.2014.114"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"89.Higgins D F, Kimura K, Bernhardt W M. (2007) Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. , J Clin Invest 117-3810.","DOI":"10.1172\/jci30487"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"90.He L, Wei Q, Liu J. (2017) AKI on CKD: heightened injury, suppressed repair, and the underlying mechanisms. Kidney Int. 92, 1071-1083.","DOI":"10.1016\/j.kint.2017.06.030"},{"key":"ref90","doi-asserted-by":"publisher","unstructured":"91.Takaori K, Yanagita M. (2016) Insights into the Mechanisms of the Acute Kidney Injury-to-Chronic Kidney Disease Continuum. Nephron. 134-172.","DOI":"10.1159\/000448081"},{"key":"ref91","doi-asserted-by":"publisher","unstructured":"92.Theilig F, Enke A K, Scolari B, Polzin D, Bachmann S et al.Tubular deficiency of von Hippel-Lindau attenuates renal disease progression in anti-GBM glomerulonephritis. The American journal of pathology 2011;. 179-2177.","DOI":"10.1016\/j.ajpath.2011.07.012"},{"key":"ref92","doi-asserted-by":"publisher","unstructured":"93.Syn N, Wang L, Sethi G, Thiery J P, Goh B C. (2016) Exosome-mediated metastasis: from epithelial-mesenchymal transition to escape from immunosurveillance. Trends in pharmacological sciences. 37, 606-617.","DOI":"10.1016\/j.tips.2016.04.006"},{"key":"ref93","doi-asserted-by":"publisher","unstructured":"94.Yeh Y C, Wei W C, Wang Y K, Lin S C, Sung J M et al.Transforming growth factor-\u03b21 induces Smad3-dependent \u03b21 integrin gene expression in epithelial-to-mesenchymal transition during chronic tubulointerstitial fibrosis. The American journal of pathology 2010;. 177-1743.","DOI":"10.2353\/ajpath.2010.091183"},{"key":"ref94","doi-asserted-by":"publisher","unstructured":"95.Xu J, Lamouille S, Derynck R. (2009) TGF-\u03b2-induced epithelial to mesenchymal transition. Cell Res. 19, 156-172.","DOI":"10.1038\/cr.2009.5"},{"key":"ref95","doi-asserted-by":"publisher","unstructured":"96.Vanholder R, Schepers E, Pletinck A, Nagler E V, Glorieux G. (2014) The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. , J Am Soc Nephrol 25, 1897-1907.","DOI":"10.1681\/asn.2013101062"},{"key":"ref96","doi-asserted-by":"publisher","unstructured":"97.Sun C Y, Chang S C, Wu M S. (2012) Uremic toxins induce kidney fibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition. PLoS One. 7, 34026.","DOI":"10.1371\/journal.pone.0034026"},{"key":"ref97","doi-asserted-by":"publisher","unstructured":"98.Kim S H, Yu M A, Ryu E S, Jang Y H, Kang D H. (2012) Indoxyl sulfate-induced epithelial-to-mesenchymal transition and apoptosis of renal tubular cells as novel mechanisms of progression of renal disease. Laboratory investigation; a journal of technical methods and pathology. 92, 488-498.","DOI":"10.1038\/labinvest.2011.194"},{"key":"ref98","doi-asserted-by":"publisher","unstructured":"99.Bolati D, Shimizu H, Niwa T. (2012) AST-120 ameliorates epithelial-to-mesenchymal transition and interstitial fibrosis in the kidneys of chronic kidney disease rats. , Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 22, 176-180.","DOI":"10.1053\/j.jrn.2011.10.015"},{"key":"ref99","doi-asserted-by":"publisher","unstructured":"100.Lau W L, Savoj J, Nakata M B, Vaziri N D. (2018) Altered microbiome in chronic kidney disease: systemic effects of gut-derived uremic toxins. Clin Sci. 132-509.","DOI":"10.1042\/cs20171107"},{"key":"ref100","doi-asserted-by":"publisher","unstructured":"101.Brito J S, Borges N A, Dolenga C J, Carraro-Eduardo J C, Nakao L S et al. (2016) Is there a relationship between tryptophan dietary intake and plasma levels of indoxyl sulfate in chronic kidney disease patients on hemodialysis?. Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia 38, 396-402.","DOI":"10.5935\/0101-2800.20160064"},{"key":"ref101","doi-asserted-by":"publisher","unstructured":"102.Nazzal L, Roberts J, Singh P. (2017) Microbiome perturbation by oral vancomycin reduces plasma concentration of two gut-derived uremic solutes, indoxyl sulfate and p-cresyl sulfate, in end-stage renal disease. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 32, 1809-1817.","DOI":"10.1093\/ndt\/gfx029"},{"key":"ref102","doi-asserted-by":"publisher","unstructured":"103.Barreto F C, Barreto D V, Liabeuf S. (2009) Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. , Clinical journal of the American Society of Nephrology : CJASN 4, 1551-1558.","DOI":"10.2215\/cjn.03980609"},{"key":"ref103","unstructured":"104.Miyazaki T, Ise M, Seo H, Niwa T. (1997) Indoxyl sulfate increases the gene expressions of TGF-beta 1, TIMP-1 and pro-alpha 1(I) collagen in uremic rat kidneys. Kidney Int Suppl. 62, 15-22."},{"key":"ref104","doi-asserted-by":"publisher","unstructured":"105.Motojima M, Hosokawa A, Yamato H, Muraki T, Yoshioka T. (2003) Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells. Kidney Int. 63, 1671-1680.","DOI":"10.1046\/j.1523-1755.2003.00906.x"},{"key":"ref105","doi-asserted-by":"publisher","unstructured":"106.Saito S, Shimizu H, Yisireyili M, Nishijima F, Enomoto A et al. (2014) Indoxyl sulfate-induced activation of (pro)renin receptor is involved in expression of TGF-beta1 and alpha-smooth muscle actin in proximal tubular cells. Endocrinology. 155-1899.","DOI":"10.1210\/en.2013-1937"},{"key":"ref106","doi-asserted-by":"publisher","unstructured":"107.Shimizu H, Yisireyili M, Nishijima F, Niwa T. (2013) Indoxyl sulfate enhances p53-TGF-beta1-Smad3 pathway in proximal tubular cells. American journal of nephrology. 37, 97-103.","DOI":"10.1159\/000346420"},{"key":"ref107","doi-asserted-by":"publisher","unstructured":"108.Galichon P, Finianos S, Hertig A. (2013) EMT-MET in renal disease: should we curb our enthusiasm? Cancer letters. 341-24.","DOI":"10.1016\/j.canlet.2013.04.018"},{"key":"ref108","doi-asserted-by":"publisher","unstructured":"109.Bolati D, Shimizu H, Higashiyama Y, Nishijima F, Niwa T. (2011) Indoxyl sulfate induces epithelial-to-mesenchymal transition in rat kidneys and human proximal tubular cells. , Am J Nephrol 34, 318-323.","DOI":"10.1159\/000330852"},{"key":"ref109","doi-asserted-by":"publisher","unstructured":"110.Meng X-M, Huang X R, Xiao J. (2012) . Disruption of Smad4 impairs TGF-\u03b2\/Smad3 and Smad7 transcriptional regulation during renal inflammation and fibrosis in vivo and in vitro. Kidney international 81, 266-279.","DOI":"10.1038\/ki.2011.327"},{"key":"ref110","doi-asserted-by":"publisher","unstructured":"111.Nariman-Saleh-Fam Z, Bastami M, Ardalan M, Sharifi S. (2018) Hosseinian Khatib SM, Zununi Vahed S. Cell-free microRNA-148a is associated with renal allograft dysfunction: Implication for biomarker discovery. , Journal of Cellular Biochemistry 0.","DOI":"10.1002\/jcb.27860"},{"key":"ref111","doi-asserted-by":"publisher","unstructured":"112.Ma Y, Shi J, Wang F. (2018) MiR-130b increases fibrosis of HMC cells by regulating the TGF-\u03b21 pathway in diabetic nephropathy. , Journal of Cellular Biochemistry 0.","DOI":"10.1002\/jcb.27688"}],"container-title":["Journal of Nephrology Advances"],"link":[{"URL":"https:\/\/openaccesspub.org\/jna\/article\/895","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T20:49:44Z","timestamp":1572641384000},"score":0.0,"resource":{"primary":{"URL":"https:\/\/openaccesspub.org\/jna\/article\/895"}},"editor":[{"given":"Ying-Yong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Northwest University, China."}],"role":[{"role":"editor","vocabulary":"crossref"}]}],"issued":{"date-parts":[[2018,11,12]]},"references-count":112,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,10,12]]}},"URL":"https:\/\/doi.org\/10.14302\/issn.2574-4488.jna-18-2443","ISSN":["2574-4488"],"issn-type":[{"type":"electronic","value":"2574-4488"}],"published":{"date-parts":[[2018,11,12]]},"article-number":"895"},{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T14:11:14Z","timestamp":1753884674319,"version":"3.41.2"},"reference-count":48,"publisher":"Open Access Pub","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JNA"],"abstract":"This study aimed to analyze pharmacological actions of phenolic compound luteolin on the renal and cardiac hypertrophy, blood pressure (BP), baroreflex sensitivity (BRS), levels of epoxyeicosatrienoic acids (EETs), prostaglandin E-2 (PGE-2) and endothelin-1 (E1) in plasma in the 2 kidney - 1 clip (2K-1C) model of renovascular hypertension (RVH).\n\nAll animals, were randomized into 2 groups: control (normal) I - sham-operated, II- RVH male Wistar rats, which after 4 weeks of surgical intervention secondly randomized to control II group, treated 0.1% dimethyl sulphoxide (DMSO) and main group - with luteolin in 15 DMSO, 3 mg\/kg body weight, intraperitonially, during 2 weeks. ET-1, EETs and PGE2 levels investigated in carotid artery blood plasma and analyzed using ELISA kits. All data statistically analyzed using the SPSS-10.0 program.\n\nIn RVH rats BP increased by 32%, cardiac and right kidney hypertrophy and reduction in parasympathetic component of BRS by 40% and sympathetic by 39%. The plasma level of total trans-EETs and PGE2 in RVH rats decreased by 44% and 50% respectively, while the level of ET-1 increased by 67%. Two weeks treatment with luteolin lowered BP, improved parasympathetic, without marked changes in sympathetic component of BRS. Deremodeling of cardiac and renal hypertrophy under prolonged treatment with luteolin accompanied with increasing in the level of EETs by 44%, PGE-2 by 50% and markedly reducing of plasma content of ET-1 (by 60%).\n\nInhibition of EET hydrolase using low doses of luteolin provides beneficial cardio and renoprotective action in experimental model of RVH.<\/jats:p>","DOI":"10.14302\/issn.2574-4488.jna-23-4545","type":"journal-article","created":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T12:29:02Z","timestamp":1705148942000},"page":"1-11","source":"Crossref","is-referenced-by-count":1,"title":["Baroreflex Sensitivity, Cardiac and Kidney Remodeling and Deterioration in Vasoactive Substances Content in Blood in Experimental Model of Renovascular Hypertension. Action of Natural Flavone, Luteolin"],"prefix":"10.14302","volume":"`","author":[{"given":"N.A.","family":"Papiashvili","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Technology, Tbilisi State Medical University, Tbilisi, Georgia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.V.","family":"Ghonghadze","sequence":"additional","affiliation":[{"name":"Department of Medical Pharmacology, Tbilisi State Medical University, Tbilisi, Georgia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.V.","family":"Sharikadze","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Ilia State University, Tbilisi, Georgia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. P.","family":"Khutsishvili","sequence":"additional","affiliation":[{"name":"Laboratory of Biochemistry of Meta Clinic, Tbilisi, Georgia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.A.","family":"Bakuridze","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, Tbilisi State Medical University, Tbilisi, Georgia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.J.","family":"Bakuridze","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, Tbilisi State Medical University, Tbilisi, Georgia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.V.","family":"Sukoyan","sequence":"additional","affiliation":[{"name":"International Scientific Center of introduction of New Biomedical Technology, Tbilisi, Georgia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.V.","family":"Gongadze","sequence":"additional","affiliation":[{"name":"Department of Medical Pharmacology, Tbilisi State Medical University, Tbilisi, Georgia."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5410","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"unstructured":"1. (2003) . Seventh Report of the Joint Committee on Prevention, Definition, Evaluation and Treatment of High Blood Pressure. Hypertension 42, 1206-1256.","key":"ref0"},{"doi-asserted-by":"publisher","unstructured":"2.Ettehad D, Emdin C A, Anderson SG KiranA, Callender T. (2016) Blood pressure lowering for prevention of cardiovascular disease and death. A systematic review and meta-analysis. , Lancet 387(10022), 957-967.","key":"ref1","DOI":"10.1016\/s0140-6736(15)01225-8"},{"doi-asserted-by":"publisher","unstructured":"3.Duarte J, Pallencia R P, Vargas F, Ocete M A, Vizcaino F P. (2001) Antihypertensive effects of the flavonoid quercetin in spontaneously hypertensive rats. , British J. Pharmacol 133(1), 117-124.","key":"ref2","DOI":"10.1038\/sj.bjp.0704064"},{"doi-asserted-by":"publisher","unstructured":"4.H\u00f6rnsten C, Weidung B, Littbrand H, Carlberg B, Nordstr\u00f6m P. (2016) High blood pressure as a risk factor for incident stroke among very old people: a population-based cohort study. , J. of Hypertension 34(10), 2059-2065.","key":"ref3","DOI":"10.1097\/hjh.0000000000001048"},{"doi-asserted-by":"crossref","unstructured":"5.Imig J D. (2019) Epoxyeicosanoides in hypertension. https:\/doi.org\/10.33549\/physion res934291 , Physiol. Res 68, 695-704.","key":"ref4","DOI":"10.33549\/physiolres.934291"},{"unstructured":"6.Ong C E, Pan Y, Mak J W. (2017) The roles of cytochromes P-450 in vascular biology and cardiovascular homeostasis. www.ijcem.com \/ISSN: , Int. J. Clin. Exp. Med 10(1), 1624-1636.","key":"ref5"},{"doi-asserted-by":"publisher","unstructured":"7.Abdel-Sayed S, Nussberger J, Aubert J E, Gohlke P, Brunner H R et al. (2003) Measurement of plasma endothelin-1 in experimental hypertension and in healthy subjects. , Am.J. Hypertens 16(7), 515-521.","key":"ref6","DOI":"10.1016\/s0895-7061(03)00903-8"},{"doi-asserted-by":"crossref","unstructured":"8.E L Schiffrin. (2000) Endothelin: Role in experimental hypertension. , Journal of Cardiovascular Pharmacology 35(4), 33-35.","key":"ref7","DOI":"10.1097\/00005344-200000002-00008"},{"doi-asserted-by":"publisher","unstructured":"9.Swan C E, Breyer R M. (2011) Prostaglandin E2 modulation of blood pressure homeostasis: studies in rodent models. Prostaglandins and other lipid mediators. 96, 1-4.","key":"ref8","DOI":"10.1016\/j.prostaglandins.2011.07.001"},{"doi-asserted-by":"publisher","unstructured":"10.Fleming J. (2014) The pharmacology of the cytochrome P-450 epoxygenase\/soluble epoxide hydrolase axis in vasculature and cardiovascular disease. Pharmacological Reviews. 66(4), 1106-1140.","key":"ref9","DOI":"10.1124\/pr.113.007781"},{"doi-asserted-by":"publisher","unstructured":"11.Capdevila J, Wang W. (2013) Role of cytochrome p-450 epoxygenase in regulating renal membrane transport and hypertension. , Curr. Opin. Nephrol. Hypertens 22, 163-169.","key":"ref10","DOI":"10.1097\/mnh.0b013e32835d911e"},{"doi-asserted-by":"publisher","unstructured":"12.Chen C, Lai J. (2021) The role of epoxyeicosatrienoic acids in cardiac remodeling. Frontiers in Physiology. 12. https: doi.org\/10.3389\/fphys.2021.642470","key":"ref11","DOI":"10.3389\/fphys.2021.642470"},{"doi-asserted-by":"publisher","unstructured":"13.Fan F, Muroya Y, Roman R J. (2015) Cytochrome P-450 eicosanoids in hypertension and renal disease. Current Opinion in Nephrology and Hypertension 24(1), 37-46.","key":"ref12","DOI":"10.1097\/mnh.0000000000000088"},{"doi-asserted-by":"publisher","unstructured":"14.Node K, Huo Y, Ruan X, Yang B, Speaker M. (1999) Antiinflammatory properties of cytochrome p-450 epoxygenase-derived eicosanoids. , Science 285, 1276-1279.","key":"ref13","DOI":"10.1126\/science.285.5431.1276"},{"doi-asserted-by":"crossref","unstructured":"15.Yang L, Maki-Petaja K, Cheriyan J, Wilkinson IB McEnieryC. (2015) The role of epoxyeicosatrienoic acids in the cardiovascular system. , British J. of Clin. Pharmacol 80(1), 28-44.","key":"ref14","DOI":"10.1111\/bcp.12603"},{"doi-asserted-by":"crossref","unstructured":"16.Yang L, Maki-Petaja K, Cheriyan J, Wilkinson IB McEnieryC. (2015) The role of epoxyeicosatrienoic acids in the cardiovascular system. , British J. of Clin. Pharmacol 80(1), 28-44.","key":"ref15","DOI":"10.1111\/bcp.12603"},{"doi-asserted-by":"publisher","unstructured":"17.Yang T, Peng R, Guo Y, Shen L, Zhao S et al. (2013) The role of 14,15-dihydroxyeicosatrienoic acid levels in inflammation and its relationship to lipoproteins. Lipids Health Dis. 12, 151-10.","key":"ref16","DOI":"10.1186\/1476-511x-12-151"},{"doi-asserted-by":"crossref","unstructured":"18. (2011) Increases in plasma trans-EETs and blood pressure reduction in spontaneously hypertensive rats. , Am. J. Physiol. Heart Circ. Physiol 300(6), 1990-1996.","key":"ref17","DOI":"10.1152\/ajpheart.01267.2010"},{"doi-asserted-by":"publisher","unstructured":"19.Khan A H, Pavlov T S, Christain S V, Neckar J, Staruschenko A. (2014) Epoxyeicosatrienoic acid analogue lowers blood pressure through vasodilation and sodium channel inhibition. , Clin. Sci 127(7), 463-474.","key":"ref18","DOI":"10.1042\/cs20130479"},{"doi-asserted-by":"publisher","unstructured":"20.Papiashvili N, Bakuridze K, Ghongadze M, Bakuridze A, Gongadze N. (2022) Influence of plant origin soluble epoxide hydrolase inhibitors on hemodynamic parameters in hypertensive rats. Mat. of 15th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT) , Athens, Greece, Eur J Clin Pharmacol 78, 25-28.","key":"ref19","DOI":"10.1007\/s00228-022-03333-y"},{"doi-asserted-by":"publisher","unstructured":"21.Honetschlagerova Z, Sporkova A, Kopkah L, Huskova Z, Hwang S H. (2011) Inhibition of soluble epoxide hydrolase improves the impaired pressure natriuresis relationship and attenuates the development of hypertension and hypertension-associated end \u2013 organ damage in Cyp 1a 1-Ren-2transgenic rats. , J. Hypertension 29, 1590-1601.","key":"ref20","DOI":"10.1097\/hjh.0b013e328349062f"},{"doi-asserted-by":"publisher","unstructured":"22.Loch D, Hoey A, Morisseau C, Hammock B O, Brown L. (2007) Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. https: link , Cell Biochemistry and Biophysics 47, 87-97.","key":"ref21","DOI":"10.1385\/cbb:47:1:87"},{"doi-asserted-by":"publisher","unstructured":"23.Morisseau C, Hammock B D. (2005) Epoxide hydrolases: Mechanisms, inhibitor designs and biological roles. , Annu. Rev. Pharmacol. Toxicol 45, 311-333.","key":"ref22","DOI":"10.1146\/annurev.pharmtox.45.120403.095920"},{"doi-asserted-by":"publisher","unstructured":"24.Morisseau C, Hammock B D. (2013) Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health. , Annual Review of Pharmacology and Toxicology 53, 37-58.","key":"ref23","DOI":"10.1146\/annurev-pharmtox-011112-140244"},{"doi-asserted-by":"publisher","unstructured":"25.Yu Z, Xu F, Huse L M, Morisseau C, Draper A. (2000) Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. , Circ.Res 87, 992-998.","key":"ref24","DOI":"10.1161\/01.res.87.11.992"},{"doi-asserted-by":"publisher","unstructured":"26. (2005) An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. , Hypertension 46(4), 975-981.","key":"ref25","DOI":"10.1161\/01.hyp.0000176237.74820.75"},{"doi-asserted-by":"publisher","unstructured":"27.Kim J H, Jin C H. (2020) Inhibitory activity of flavonoids, Chrisoeriol and Luteolin-7-0-Glucopiranozide on soluble epoxide hydrolase from capsicum chinense Biomolecules. 10(2), 180-10.","key":"ref26","DOI":"10.3390\/biom10020180"},{"doi-asserted-by":"publisher","unstructured":"28.Olaleye M T, Grown O O, Akinmoladun A C, Akindahunsi A A. (2014) Rutin and quercetin show greater efficacy than nifedipin in ameliorating hemodynamic, redox and metabolic imbalances in sodium chloride-induced hypertensive rats. Human Exper Toxicol. 33(6), 602-608.","key":"ref27","DOI":"10.1177\/0960327113504790"},{"unstructured":"29.Zhao X, Yamamoto T, Newman J W, Kim I H, Watanabe T. (2004) Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. , J. Am Soc. Nephrol 15, 1244-1253.","key":"ref28"},{"doi-asserted-by":"publisher","unstructured":"30.Minuz P, Jiang H, Fava C, Turolo L, Tacconeli S.et al (2008). Altered release of cytochrome P-450 metabolites of arachidonic acid in renovascular disease. , Hypertension 51, 1379-85.","key":"ref29","DOI":"10.1161\/hypertensionaha.107.105395"},{"doi-asserted-by":"publisher","unstructured":"31.Bellien J, Iacob M, Remy-Jouet I, Lucas D, Montiel C. (2012) Epoxyeicosatrienoic acids contribute with altered nitric oxide and endothellin -1 pathways to conduit artery endothelial dysfunction in essential hypertension. , Circulation 125, 1266-75.","key":"ref30","DOI":"10.1161\/circulationaha.111.070680"},{"doi-asserted-by":"publisher","unstructured":"32.Gongadze N V, Kezeli T D, Sukoyan G V, Chapichadze Z.Dolidze NM et al (2016) Deterioration in Hemodynamics Reaction, Baroreflex sensitivity, sympathetic nerve activity and redox state of thoracic aorta in experimental model of nitrate tolerance and its pharmacological correction. , Pharmacology& 7, 81-88.","key":"ref31","DOI":"10.4236\/pp.2016.71011"},{"doi-asserted-by":"publisher","unstructured":"33.Kezeli T D, Gongadze N V, Sukoyan G V, Shikhashvili M, Chapichadze Z. (2019) Circadian variation in vasoconstriction and vasodilatation mediators and baroreflex sensitivity in hypertensive rats. , J of Circadian Rhythms 17(1), 1-8.","key":"ref32","DOI":"10.5334\/jcr.185"},{"doi-asserted-by":"publisher","unstructured":"34.Aliwarga T, Guo X, Evangelista E A, R N Lemaitre, Sotoodehnia N. (2020) Higher epoxyeicosatrienoic acids in cardiomyocytes specific cyp 2J2 transgenic mice are associated with improved myocardial remodeling. , Biomedicines 8, 144-10.","key":"ref33","DOI":"10.3390\/biomedicines8060144"},{"doi-asserted-by":"publisher","unstructured":"35.MMO Monteiro, Franca-Silva M S, NFB Alves, SKP Porpino, Braga V A. (2012) Quercetin improves baroreflex sensitivity in spontaneously hypertensive rats. , Molecules 17(11), 12997-13008.","key":"ref34","DOI":"10.3390\/molecules171112997"},{"doi-asserted-by":"publisher","unstructured":"36.Si H, R P Wyeth, Liu D.The flavonoid luteolin induces nitric oxide production and arterial relaxation. , Eur. J. Nutr 53(1), 269-275.","key":"ref35","DOI":"10.1007\/s00394-013-0525-7"},{"unstructured":"37.Dunn M J, Grone H J. (1985) The relevance of prostaglandins in human hypertension Adv. Prostaglandin Thromboxane Leukot Res. 13, 179-187.","key":"ref36"},{"doi-asserted-by":"publisher","unstructured":"38.Herrera M, Yang T, M A Sparks, Manning M W, Koller B H et al. (2019) Complex role for -E-prostanoid 4 receptors in hypertension. , Journal of the American Heart Association 2019, 116-118.","key":"ref37","DOI":"10.1161\/jaha.118.010745"},{"doi-asserted-by":"publisher","unstructured":"39.Xu M, Y P Lu, Hasan A A, Hocher B. (2017) Plasma ET-1 concentration are elevated in patients with hypertension. Meta-analysis of clinical studies. Kidney blood pressure research. 42, 304-313.","key":"ref38","DOI":"10.1159\/000477572"},{"doi-asserted-by":"publisher","unstructured":"40.CJG Alonso, Feldstein C A, Juncos L A, J C Romero. (2005) Role of endothelin in the pathogenesis of hypertension. Mayo Clin. Proc 80(1), 84-96.","key":"ref39","DOI":"10.4065\/80.1.84"},{"doi-asserted-by":"crossref","unstructured":"41.Kozakai T, YamanakaA.IchibaT, ToyokawaT, KamadaY et al (2005) Luteolin inhibits endothelin-1 secretion in cultured endothelial cells. , Biosci Biotechnol Biochem 69(8), 1613-5.","key":"ref40","DOI":"10.1271\/bbb.69.1613"},{"doi-asserted-by":"publisher","unstructured":"42.Jia Z, Nallasamy P, Liu D, Shah H, Li J Z.Et al (2015) Luteolin protects against vascular inflammation in mice and TNF-alpha-induced monocyte adhesion to endothelial cells via suppressing IKBa\/NF-kB signaling pathway. , J Nutr Biochem 26, 293-302.","key":"ref41","DOI":"10.1016\/j.jnutbio.2014.11.008"},{"doi-asserted-by":"publisher","unstructured":"43.Al-Qattan K K, Khan I, M A Alnaqueeb, Ali M. (2001) Tromboxane-B2, prostaglandin-E2 and hypertension in the rat 2-kidney 1 clip model: a possible mechanism of the garlic induced hypotension. , Prostaglandins. Leukot. Essent. Fatty 64(1), 5-10.","key":"ref42","DOI":"10.1054\/plef.2000.0232"},{"doi-asserted-by":"publisher","unstructured":"44.Li X, Chu G, Zheng Z, Wang X, Zhang G. (2020) Epoxyeicosatrienoic acid prevents maladaptive remodeling in pressure overload by targeting calcineurin \/NFAT and smad-7. Exp Cell Res. 386, 1016.","key":"ref43","DOI":"10.1016\/j.yexcr.2019.111716"},{"doi-asserted-by":"publisher","unstructured":"45.Neckar J, MAH Khan, Gross G, Cyprova M, al Hardicha J at. (2019) Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in SHR. Clein sci. , (Lond) 133, 939-951.","key":"ref44","DOI":"10.1042\/cs20180728"},{"doi-asserted-by":"publisher","unstructured":"46.Ronchi S N, Brasil G A, AMD Nascimento, EMD Lima, Scherer R. (2015) Phytochemical and in vitro and in vivo biological investigation of the antihypertensive activity of mango leaves (Mangifera indica L.) Ther Advan Cardiovasc Dis. 9-5.","key":"ref45","DOI":"10.1177\/1753944715572958"},{"unstructured":"47.Xagorari A, Papapetropoules A, Mauromatis A, Economou M, Fotsis T et al. (2001) Luteolin inhibits an endotoxin-stimulated phosphorylation cascade and proinflammatory cytokine production in macrophages. , J. Pharmacol. Exp. Ther 181-187.","key":"ref46"},{"doi-asserted-by":"publisher","unstructured":"48.Lampanichakul M, Poasakata A, Potue P, Rottanakanokchai S, Maneesai P. (2022) Nobiletin resolves left ventricular and renal changes in 2K-1C hupertensive rats. Scientific reports. 12, 9289-10.","key":"ref47","DOI":"10.1038\/s41598-022-13513-6"}],"container-title":["Journal of Nephrology Advances"],"link":[{"URL":"https:\/\/openaccesspub.org\/jna\/article\/1967","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T12:29:09Z","timestamp":1705148949000},"score":0.0,"resource":{"primary":{"URL":"https:\/\/openaccesspub.org\/jna\/article\/1967"}},"issued":{"date-parts":[[2023,5,15]]},"references-count":48,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,5,15]]}},"URL":"https:\/\/doi.org\/10.14302\/issn.2574-4488.jna-23-4545","ISSN":["2574-4488"],"issn-type":[{"type":"electronic","value":"2574-4488"}],"published":{"date-parts":[[2023,5,15]]},"article-number":"1967"},{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T14:10:35Z","timestamp":1753884635353,"version":"3.41.2"},"reference-count":15,"publisher":"Open Access Pub","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JNA"],"abstract":"The function of the thyroid gland is one of the most important in the human body as it regulates the majority of the body's physiological actions. The thyroid produces hormones (T3 and T4) that have many actions including metabolism, development, protein synthesis, and the regulation of many other important hormones. There is a lot of interaction between the kidney and thyroid gland during the disease States thyroid hormones have a major role in regulating the glomerular filtration rate through its hormonal actions in normal physiology. But these things are altered in the disease States such as chronic kidney disease. It is a well-known fact that hypothyroidism causes decreased Glomerular filtration rate whereas hyperthyroidism causes increased Glomerular filtration rate leading to renin-angiotensin-aldosterone system activation. In our study we aim to see the prevalence of low T3 syndrome in different stages of CKD which is a state of physiological benefit in preserving the proteins lost through the Kidneys in CKD patients and since CKD is progressed in hyperthyroidism state it is a protective mechanism in restoring the CKD status. Other subclinical hypothyroidism hyperthyroidism. Autoimmune hypothyroidism. Glomerulonephritis are all part of a dynamic endocrine and nephrology sequence. Thorough knowledge of these is required for optimum treatment of thyroid in CKD patients.<\/jats:p>","DOI":"10.14302\/issn.2574-4488.jna-21-4039","type":"journal-article","created":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T12:27:19Z","timestamp":1670675239000},"page":"31-34","source":"Crossref","is-referenced-by-count":1,"title":["Thyroid Function Abnormalities in Patients with Chronic Kidney Disease"],"prefix":"10.14302","volume":"1","author":[{"given":"A K Al","family":"Miraj","sequence":"first","affiliation":[{"name":"Research Assistant, Department of Vascular surgery Bangabandhu Sheikh Mujib Medical University (BSMMU) Dhaka, Bangladesh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magfur","family":"Rahman","sequence":"additional","affiliation":[{"name":"Medical Officer Cardiac Surgery Department, Bangabandhu Sheikh Mujib Medical University (BSMMU) Dhaka, Bangladesh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anwarul","family":"Hoque Faraji","sequence":"additional","affiliation":[{"name":"Associate professor of Nephrology, Colonel Maleq Medical college Mnikgangue Bangladesh."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Abduz Zaher","sequence":"additional","affiliation":[{"name":"Associate Professor, Institute of Nutrition and Food Science, University of Dhaka Bangladesh."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Ata Ullah","sequence":"additional","affiliation":[{"name":"Assistant Professor Department of Cardiac Surgery, Bangabandhu Sheikh Mujib Medical University (BSMMU) Dhaka, Bangladesh."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5410","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"key":"ref0","unstructured":"1.Joanne M B, Karl S K. (2011) Chronic kidney disease. In: Dan LL. Harrison\u2019s Principles of Internal Medicine.McGraw Hill, USA , Anthony 2(18), 2289-2293."},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2.Jabbar Z, Aggarwal P K, Chandel N, Kohli H S, Gupta K L et al. (2009) High prevalence of vitamin D deficiency in north Indian adults is exacerbated in those with chronic kidney disease. Nephrology. 14(3), 345-9.","DOI":"10.1111\/j.1440-1797.2008.01082.x"},{"key":"ref2","unstructured":"3.Robert W S. (2007) Abnormalities in the thyroid gland and hypothalamo pituitary thyroid axis in patients with CKD Diseases of the kidney and urinary tract, eighth edition. 3, 2518."},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4.Kaptein E M, Quion-Verde H, Massry S G. (1984) Hemodynamic effects of thyroid hormone. Contributions to Nephrology.","DOI":"10.1159\/000429278"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5.Mohamedali M, Reddy Maddika S, Vyas A, Iyer V, Cheriyath P. (2014) Thyroid disorders and chronic kidney disease. International journal of nephrology. 14, 1-6.","DOI":"10.1155\/2014\/520281"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6.Levey A S, Coresh J, Balk E, Kausz A T, Levin A et al. (2003) National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Annals of internal medicine. 139(2), 137-47.","DOI":"10.7326\/0003-4819-139-2-200307150-00013"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7.Feinstein E I, Kaptein E M, Nicoloff J T, Massry S G. (1982) Thyroid function in patients with nephrotic syndrome and normal renal function. American journal of nephrology. 2(2), 70-6.","DOI":"10.1159\/000166587"},{"key":"ref7","unstructured":"8.Dudani R A. (1981) Thyroid dysfunction in Uremia. , Journal Assoc Physicians India 29, 1037-40."},{"key":"ref8","unstructured":"9.Quionverde H, Kaptein E M, Rodriguez H, Massry S. (1984) Prevalence of thyroid-disease in chronic-renal failure (CRF) and dialysis patients. In KIDNEY INTERNATIONAL350 MAIN ST, MALDEN, MA02148: BLACKWELL SCIENCE INC 25(1), 190-190."},{"key":"ref9","unstructured":"10.Joseph L J, Desai K B, Mehta H J, Mehta M N, Almeida A F et al. (1993) Measurement of serum thyrotropin levels using sensitive immunoradiometric assays in patients with chronic renal failure: alterations suggesting an intact pituitary thyroid axis. Thyroidology. 5(2), 35-9."},{"key":"ref10","unstructured":"11.Karunanidhi A. (1979) Thyroid function in patients with chronic renal failure. , Indian J Med Research 69, 792-7."},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12.Hardy M J, Ragbeer S S, Nascimento L. (1988) Pituitarythyroid function in chronic renal failure assessed by a highly sensitive thyrotropin assay. , The Journal of Clinical Endocrinology 66(1), 233-6.","DOI":"10.1210\/jcem-66-1-233"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13.Heged\u0171s L, Andersen J R, Poulsen L R, Perrild H, Holm B et al.Thyroid gland volume and serum concentrations of thyroid hormones in chronic renal failure. , Nephron 40(2), 171-4.","DOI":"10.1159\/000183455"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14.Iglesias P, Diez J J. (2009) Thyroid dysfunction and kidney disease. European journal of endocrinology. 160(4), 503-15.","DOI":"10.1530\/EJE-08-0837"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15.Couser W G, Remuzzi G, Mendis S, Tonelli M. (2011) The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney international. 80(12), 1258-70.","DOI":"10.1038\/ki.2011.368"}],"container-title":["Journal of Nephrology Advances"],"link":[{"URL":"https:\/\/openaccesspub.org\/jna\/article\/1765","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T12:27:27Z","timestamp":1670675247000},"score":0.0,"resource":{"primary":{"URL":"https:\/\/openaccesspub.org\/jna\/article\/1765"}},"editor":[{"given":"Elbaih","family":"zico","sequence":"additional","affiliation":[{"name":"Associate professor of emergency medicine, Faculty of Medicine, Suez Canal University, Ismailia, Egypt."}],"role":[{"role":"editor","vocabulary":"crossref"}]}],"issued":{"date-parts":[[2022,2,3]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,12,16]]}},"URL":"https:\/\/doi.org\/10.14302\/issn.2574-4488.jna-21-4039","ISSN":["2574-4488"],"issn-type":[{"type":"electronic","value":"2574-4488"}],"published":{"date-parts":[[2022,2,3]]},"article-number":"1765"},{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T15:54:44Z","timestamp":1648914884293},"reference-count":0,"publisher":"Open Access Pub","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JNA"],"DOI":"10.14302\/issn.2574-4488.jna-16-1225","type":"journal-article","created":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T07:11:30Z","timestamp":1509433890000},"page":"1-3","source":"Crossref","is-referenced-by-count":1,"title":["ARTERIOVENOUS FISTULA IN A PATIENT WITH ABERRANT RADIAL ARTERY"],"prefix":"10.14302","volume":"1","author":[{"given":"Sachin S.","family":"Soni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shriganesh R.","family":"Barnela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonali S.","family":"Saboo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish V.","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirish S.","family":"Deshmukh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Unmesh V.","family":"Takalkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5410","published-online":{"date-parts":[[2016,10,12]]},"container-title":["Journal of Nephrology Advances"],"deposited":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T07:11:31Z","timestamp":1509433891000},"score":0.0,"resource":{"primary":{"URL":"http:\/\/openaccesspub.org\/jna\/article\/365"}},"editor":[{"given":"Haichun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"issued":{"date-parts":[[2016,10,12]]},"references-count":0,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,10,12]]}},"URL":"https:\/\/doi.org\/10.14302\/issn.2574-4488.jna-16-1225","ISSN":["2574-4488"],"issn-type":[{"value":"2574-4488","type":"electronic"}],"published":{"date-parts":[[2016,10,12]]}},{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T11:01:14Z","timestamp":1784372474882,"version":"3.55.0"},"reference-count":202,"publisher":"Open Access Pub","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"DOI":"10.14302\/issn.2574-4488.jna-14-601","type":"journal-article","created":{"date-parts":[[2017,9,10]],"date-time":"2017-09-10T02:21:28Z","timestamp":1505010088000},"page":"6-41","source":"Crossref","is-referenced-by-count":5,"title":["The Toxicity of Iodinated Radiographic Contrast Agents in the Clinical Practice"],"prefix":"10.14302","volume":"1","author":[{"given":"Andreucci","family":"Michele","sequence":"first","affiliation":[{"name":"1 Nephrology Unit, Department of \u201cHealth Sciences\u201d, Campus \u201cSalvatore Venuta\u201d, \u201cMagna Graecia\u201d University, Viale Europa, loc. Germaneto, I-88100 Catanzaro, Italy (andreucci@unicz.it)"},{"name":"* Corresponding Author"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faga","family":"Teresa","sequence":"additional","affiliation":[{"name":"1 Nephrology Unit, Department of \u201cHealth Sciences\u201d, Campus \u201cSalvatore Venuta\u201d, \u201cMagna Graecia\u201d University, Viale Europa, loc. Germaneto, I-88100 Catanzaro, Italy (andreucci@unicz.it)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De Sarro","family":"Giovanbattista","sequence":"additional","affiliation":[{"name":"2 Clinical Pharmacology Unit, Department of \u201cHealth Sciences\u201d, \u201cMagna Graecia\u201d University, Viale Europa, loc. Germaneto, I-88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ashour","sequence":"additional","affiliation":[{"name":"1 Nephrology Unit, Department of \u201cHealth Sciences\u201d, Campus \u201cSalvatore Venuta\u201d, \u201cMagna Graecia\u201d University, Viale Europa, loc. Germaneto, I-88100 Catanzaro, Italy (andreucci@unicz.it)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5410","published-online":{"date-parts":[[2015]]},"reference":[{"key":"ref001","doi-asserted-by":"crossref","unstructured":"1. Solomon R Contrast-induced acute kidney injury: is there a risk after intravenous contrast? 2008 Clin J Am Soc Nephrol 3 1242 3 10.2215\/CJN.03470708","DOI":"10.2215\/CJN.03470708"},{"key":"ref002","doi-asserted-by":"crossref","unstructured":"2. Seaman W B Schwartz H G Cerebral arteriography with sodium acetrizoate (urokon sodium) 30% 1953 AMA Arch Surg 67 741 5","DOI":"10.1001\/archsurg.1953.01260040752012"},{"key":"ref003","doi-asserted-by":"crossref","unstructured":"3. Katzberg R W Haller C Contrast-induced nephrotoxicity: clinical landscape. doi: 10.1038\/sj.ki.5000366 Kidney Int Suppl:S3-7 2006 10.1038\/sj.ki.5000366","DOI":"10.1038\/sj.ki.5000366"},{"key":"ref004","doi-asserted-by":"crossref","unstructured":"4. Lightfoot C B Abraham R J Mammen T Abdolell M Kapur S Abraham R J Survey of radiologists\u2019 knowledge regarding the management of severe contrast material-induced allergic reactions 2009 Radiology 251 691 6 10.1148\/radiol.2513081651","DOI":"10.1148\/radiol.2513081651"},{"key":"ref005","doi-asserted-by":"crossref","unstructured":"5. Idee J M Pines E Prigent P Corot C Allergy-like reactions to iodinated contrast agents. A critical analysis 2005 Fundam Clin Pharmacol 19 263 81 10.1111\/j.1472-8206.2005.00326.x","DOI":"10.1111\/j.1472-8206.2005.00326.x"},{"key":"ref006","doi-asserted-by":"crossref","unstructured":"6. Andreucci M Solomon R Tasanarong A Side Effects of Radiographic Contrast Media: Pathogenesis, Risk Factors, and Prevention. doi: 10.1155\/2014\/741018. Biomed Res Int 2014 741018 10.1155\/2014\/741018","DOI":"10.1155\/2014\/741018"},{"key":"ref007","doi-asserted-by":"crossref","unstructured":"7. Singh J Daftary A Iodinated contrast media and their adverse reactions 2008 J Nucl Med Technol 36 69 74 10.2967\/jnmt.107.047621","DOI":"10.2967\/jnmt.107.047621"},{"key":"ref008","doi-asserted-by":"crossref","unstructured":"8. Thomson K Safe use of radiographic contrast media 2010 Aust Prescr 33 19 22","DOI":"10.18773\/austprescr.2010.006"},{"key":"ref009","doi-asserted-by":"crossref","unstructured":"9. Loh S Bagheri S Katzberg R W Fung M A Li C S Delayed adverse reaction to contrast-enhanced CT: a prospective single-center study comparison to control group without enhancement 2010 Radiology 255 764 71 10.1148\/radiol.10091848","DOI":"10.1148\/radiol.10091848"},{"key":"ref010","doi-asserted-by":"crossref","unstructured":"10. Schild H H Kuhl C K Hubner-Steiner U Bohm I Speck U Adverse events after unenhanced and monomeric and dimeric contrast-enhanced CT: a prospective randomized controlled trial 2006 Radiology 240 56 64 10.1148\/radiol.2393050560","DOI":"10.1148\/radiol.2393050560"},{"key":"ref011","doi-asserted-by":"crossref","unstructured":"11. Gallelli L Ferreri G Colosimo M Pirritano D Guadagnino L Pelaia G Maselli R De Sarro GB Adverse drug reactions to antibiotics observed in two pulmonology divisions of Catanzaro, Italy: a six-year retrospective study 2002 Pharmacol Res 46 395 400","DOI":"10.1016\/S1043661802002104"},{"key":"ref012","doi-asserted-by":"crossref","unstructured":"12. Gallelli L Ferreri G Colosimo M Pirritano D Flocco M A Pelaia G Maselli R De Sarro GB Retrospective analysis of adverse drug reactions to bronchodilators observed in two pulmonary divisions of Catanzaro, Italy 2003 Pharmacol Res 47 493 9","DOI":"10.1016\/S1043-6618(03)00003-3"},{"key":"ref013","doi-asserted-by":"crossref","unstructured":"13. Gallelli L Nardi M Prantera T Barbera S Raffaele M Arminio D Pirritano D Colosimo M Maselli R Pelaia G P De Gregorio De Sarro GB Retrospective analysis of adverse drug reactions induced by gemcitabine treatment in patients with non-small cell lung cancer 2004 Pharmacol Res 49 259 63","DOI":"10.1016\/j.phrs.2003.10.001"},{"key":"ref014","doi-asserted-by":"crossref","unstructured":"14. Gallelli L Gallelli A Vero G Roccia F Pelaia G G De Sarro Maselli R Acute renal failure probably induced by prulifloxacin in an elderly woman : a first case report 2006 Clin Drug Investig 26 49 53","DOI":"10.2165\/00044011-200626010-00007"},{"key":"ref015","unstructured":"15. Scicchitano F Giofre C Palleria C Mazzitello C Ciriaco M Gallelli L Paletta L Marrazzo G S De Fazio Menniti M Curia R Arena C Chimirri S Patane M Esposito S Cilurzo F Staltari O Russo E G De Sarro Pharmacovigilance and drug safety 2011 in Calabria (Italy): Adverse events analysis 2012 J Res Med Sci 17 872 5"},{"key":"ref016","unstructured":"16. Palleria C A Di Paolo Giofre C Caglioti C Leuzzi G Siniscalchi A G De Sarro Gallelli L Pharmacokinetic drug-drug interaction and their implication in clinical management 2013 J Res Med Sci 18 601 10"},{"key":"ref017","doi-asserted-by":"crossref","unstructured":"17. Sendeski M M Pathophysiology of renal tissue damage by iodinated contrast media 2011 Clin Exp Pharmacol Physiol 38 292 9 10.1111\/j.1440-1681.2011.05503.x","DOI":"10.1111\/j.1440-1681.2011.05503.x"},{"key":"ref018","doi-asserted-by":"crossref","unstructured":"18. AJ Van der Molen Thomsen H S Morcos SK and Contrast Media Safety Committee ESoUR (2004) Effect of iodinated contrast media on thyroid function in adults Eur Radiol 14 902 7 10.1007\/s00330-004-2238-z","DOI":"10.1007\/s00330-004-2238-z"},{"key":"ref019","doi-asserted-by":"crossref","unstructured":"19. Moisey R S McPherson S Wright M Orme S M Thyroiditis and iodide mumps following an angioplasty 2007 Nephrol Dial Transplant 22 1250 2 10.1093\/ndt\/gfl777","DOI":"10.1093\/ndt\/gfl777"},{"key":"ref020","unstructured":"20. Trumbo P Yates A A Schlicker S Poos M Dietary reference intakes: vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc 2001 J Am Diet Assoc 101 294 301 10.1016\/S0002-8223(01)00078-5"},{"key":"ref021","doi-asserted-by":"crossref","unstructured":"21. Burgi H Iodine excess 2010 Best Pract Res Clin Endocrinol Metab 24 107 15 10.1016\/j.beem.2009.08.010","DOI":"10.1016\/j.beem.2009.08.010"},{"key":"ref022","doi-asserted-by":"crossref","unstructured":"22. Leung A M Braverman L E Iodine-induced thyroid dysfunction 2012 Curr Opin Endocrinol Diabetes Obes 19 414 9 10.1097\/MED.0b013e3283565bb2","DOI":"10.1097\/MED.0b013e3283565bb2"},{"key":"ref023","doi-asserted-by":"crossref","unstructured":"23. Eng P H Cardona G R Fang S L Previti M Alex S Carrasco N Chin W W Braverman L E Escape from the acute Wolff-Chaikoff effect is associated with a decrease in thyroid sodium\/iodide symporter messenger ribonucleic acid and protein 1999 Endocrinology 140 3404 10","DOI":"10.1210\/en.140.8.3404"},{"key":"ref024","doi-asserted-by":"crossref","unstructured":"24. Hudzik B Zubelewicz-Szkodzi\u0144ska B Radiocontrast-Induced Thyroid Dysfunction: Is It Common and What Should We Do About It? 2014 Clin Endocrinol 80 322 327","DOI":"10.1111\/cen.12376"},{"key":"ref025","doi-asserted-by":"crossref","unstructured":"25. Martins M C Lima N Knobel M Medeiros-Neto G Natural course of iodine-induced thyrotoxicosis (Jodbasedow) in endemic goiter area: a 5 year follow-up 1989 J Endocrinol Invest 12 239 44","DOI":"10.1007\/BF03349973"},{"key":"ref026","doi-asserted-by":"crossref","unstructured":"26. Rhee C M Bhan I Alexander E K Brunelli S M Association between iodinated contrast media exposure and incident hyperthyroidism and hypothyroidism 2012 Arch Intern Med 172 153 9 10.1001\/archinternmed.2011.677","DOI":"10.1001\/archinternmed.2011.677"},{"key":"ref027","doi-asserted-by":"crossref","unstructured":"27. Martin F I Tress B W Colman P G Deam D R Iodine-induced hyperthyroidism due to nonionic contrast radiography in the elderly 1993 Am J Med 95 78 82","DOI":"10.1016\/0002-9343(93)90235-H"},{"key":"ref028","doi-asserted-by":"crossref","unstructured":"28. Conn J J Sebastian M J Deam D Tam M Martin F I A prospective study of the effect of nonionic contrast media on thyroid function 1996 Thyroid 6 107 10","DOI":"10.1089\/thy.1996.6.107"},{"key":"ref029","doi-asserted-by":"crossref","unstructured":"29. Hintze G Blombach O Fink H Burkhardt U Kobberling J Risk of iodine-induced thyrotoxicosis after coronary angiography: an investigation in 788 unselected subjects 1999 Eur J Endocrinol 140 264 7","DOI":"10.1530\/eje.0.1400264"},{"key":"ref030","doi-asserted-by":"crossref","unstructured":"30. Gartner W Weissel M Do iodine-containing contrast media induce clinically relevant changes in thyroid function parameters of euthyroid patients within the first week? 2004 Thyroid 14 521 4 10.1089\/1050725041517075","DOI":"10.1089\/1050725041517075"},{"key":"ref031","doi-asserted-by":"crossref","unstructured":"31. Katzberg R W Urography into the 21st century: new contrast media, renal handling, imaging characteristics, and nephrotoxicity 1997 Radiology 204 297 312","DOI":"10.1148\/radiology.204.2.9240511"},{"key":"ref032","doi-asserted-by":"crossref","unstructured":"32. Heinrich M C Kuhlmann M K Grgic A Heckmann M Kramann B Uder M Cytotoxic effects of ionic high-osmolar, nonionic monomeric, and nonionic iso-osmolar dimeric iodinated contrast media on renal tubular cells in vitro 2005 Radiology 235 843 9","DOI":"10.1148\/radiol.2353040726"},{"key":"ref033","doi-asserted-by":"crossref","unstructured":"33. Aspelin P Aubry P Fransson S G Strasser R Willenbrock R Berg K J Nephrotoxic effects in high-risk patients undergoing angiography 2003 N Engl J Med Nephrotoxicity in High-Risk Patients Study of I-O and Low-Osmolar Non-Ionic Contrast Media Study I 348 491 9 10.1056\/NEJMoa021833","DOI":"10.1056\/NEJMoa021833"},{"key":"ref034","doi-asserted-by":"crossref","unstructured":"34. Barrett B J Contrast nephrotoxicity 1994 J Am Soc Nephrol 5 125 37","DOI":"10.1681\/ASN.V52125"},{"key":"ref035","doi-asserted-by":"crossref","unstructured":"35. Barrett B J Carlisle E J Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media 1993 Radiology 188 171 8","DOI":"10.1148\/radiology.188.1.8511292"},{"key":"ref036","doi-asserted-by":"crossref","unstructured":"36. Taliercio C P Vlietstra R E Ilstrup D M Burnett J C Menke K K Stensrud S L Holmes D R A randomized comparison of the nephrotoxicity of iopamidol and diatrizoate in high risk patients undergoing cardiac angiography 1991 J Am Coll Cardiol 17 384 90","DOI":"10.1016\/S0735-1097(10)80103-2"},{"key":"ref037","doi-asserted-by":"crossref","unstructured":"37. Heinrich M C Haberle L Muller V Bautz W Uder M Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials 2009 Radiology 250 68 86 10.1148\/radiol.2501080833","DOI":"10.1148\/radiol.2501080833"},{"key":"ref038","doi-asserted-by":"crossref","unstructured":"38. Bolognese L Falsini G Schwenke C Grotti S Limbruno U Liistro F Carrera A Angioli P Picchi A Ducci K Pierli C Impact of iso-osmolar versus low-osmolar contrast agents on contrast-induced nephropathy and tissue reperfusion in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the Contrast Media and Nephrotoxicity Following Primary Angioplasty for Acute Myocardial Infarction [CONTRAST-AMI] 2012 Trial). Am J Cardiol 109 67 74 10.1016\/j.amjcard.2011.08.006","DOI":"10.1016\/j.amjcard.2011.08.006"},{"key":"ref039","doi-asserted-by":"crossref","unstructured":"39. Reed M Meier P Tamhane U U Welch K B Moscucci M Gurm H S The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials 2009 JACC Cardiovasc Interv 2 645 54 10.1016\/j.jcin.2009.05.002","DOI":"10.1016\/j.jcin.2009.05.002"},{"key":"ref040","doi-asserted-by":"crossref","unstructured":"40. Solomon R J Natarajan M K Doucet S Sharma S K Staniloae C S Katholi R E Gelormini J L Labinaz M Moreyra A E and Investigators of the CS(2007)Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease Circulation 115 3189 96 10.1161\/CIRCULATIONAHA.106.671644","DOI":"10.1161\/CIRCULATIONAHA.106.671644"},{"key":"ref041","doi-asserted-by":"crossref","unstructured":"41. Chalmers N Jackson R W Comparison of iodixanol and iohexol in renal impairment 1999 Br J Radiol 72 701 3","DOI":"10.1259\/bjr.72.859.10624328"},{"key":"ref042","doi-asserted-by":"crossref","unstructured":"42. Dyvik K Dyrstad K Tronstad A Relationship between viscosity and determined injection pressure in angiography catheters for common roentgen contrast media 1995 Acta Radiol Suppl 399 43 9","DOI":"10.1177\/0284185195036S39906"},{"key":"ref043","doi-asserted-by":"crossref","unstructured":"43. Jost G Pietsch H Sommer J Sandner P Lengsfeld P Seidensticker P Lehr S Hutter J Sieber M A Retention of iodine and expression of biomarkers for renal damage in the kidney after application of iodinated contrast media in rats 2009 Invest Radiol 44 114 23 10.1097\/RLI.0b013e318190fbd2","DOI":"10.1097\/RLI.0b013e318190fbd2"},{"key":"ref044","doi-asserted-by":"crossref","unstructured":"44. Seeliger E Lenhard D C Persson P B Contrast Media Viscosity versus Osmolality in Kidney Injury: Lessons from Animal Studies. Biomed Res Int 2014 358136 10 10.1155\/2014\/358136","DOI":"10.1155\/2014\/358136"},{"key":"ref045","doi-asserted-by":"crossref","unstructured":"45. Andreucci M [Radiographic contrast nephropathy] 2014 G Ital Nefrol 31 5","DOI":"10.1155\/2014\/691623"},{"key":"ref046","doi-asserted-by":"crossref","unstructured":"46. Andreucci M Faga T Perticone F Michael A Radiographic contrast agents, drugs useful for diagnostics, but with contrast-induced nephropathy as side effect 2014 JJ Nephro Urol.2014 1 2 11","DOI":"10.1155\/2014\/691623"},{"key":"ref047","doi-asserted-by":"crossref","unstructured":"47. Levey A S Bosch J P Lewis J B Greene T Rogers N Roth D A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation 1999 Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 461 70","DOI":"10.7326\/0003-4819-130-6-199903160-00002"},{"key":"ref048","doi-asserted-by":"crossref","unstructured":"48. Levey A S Stevens L A Schmid C H Zhang Y L Castro A F Feldman HI 3rd Kusek J W Eggers P F Van Lente Greene T Coresh J EPI Ckd A new equation to estimate glomerular filtration rate 2009 Ann Intern Med 150 604 12","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"ref049","doi-asserted-by":"crossref","unstructured":"49. Cockcroft D W Gault M H Prediction of creatinine clearance from serum creatinine 1976 Nephron 16 31 41","DOI":"10.1159\/000180580"},{"key":"ref050","doi-asserted-by":"crossref","unstructured":"50. Schwartz G J Feld L G Langford D J A simple estimate of glomerular filtration rate in full-term infants during the first year of life 1984 J Pediatr 104 849 54","DOI":"10.1016\/S0022-3476(84)80479-5"},{"key":"ref051","doi-asserted-by":"crossref","unstructured":"51. Andreucci V E Fuiano G Russo D Andreucci M 1998 Vasomotor nephropathy in the elderly. Nephrol Dial Transplant13Suppl7: 17 24","DOI":"10.1093\/ndt\/13.suppl_7.17"},{"key":"ref052","unstructured":"52. Andreucci V E Fuiano G Stanziale P Andreucci M Role of renal biopsy in the diagnosis and prognosis of acute renal failure 1998 Kidney Int Suppl 66 91 5"},{"key":"ref053","doi-asserted-by":"crossref","unstructured":"53. Andreucci M Federico S Andreucci V E Edema and acute renal failure 2001 Semin Nephrol 21 251 6","DOI":"10.1053\/snep.2001.21652"},{"key":"ref054","doi-asserted-by":"crossref","unstructured":"54. Curtis L M and Agarwal A (2007) HOpe for contrast-induced acute kidney injury Kidney Int 72 907 9 10.1038\/sj.ki.5002530","DOI":"10.1038\/sj.ki.5002530"},{"key":"ref055","doi-asserted-by":"crossref","unstructured":"55. Weisbord S D Palevsky P M Prevention of contrast-induced nephropathy with volume expansion 2008 Clin J Am Soc Nephrol 3 273 80 10.2215\/CJN.02580607","DOI":"10.2215\/CJN.02580607"},{"key":"ref056","doi-asserted-by":"crossref","unstructured":"56. Katzberg R W Newhouse J H Intravenous contrast medium-induced nephrotoxicity: is the medical risk really as great as we have come to believe? 2010 Radiology 256 21 8 10.1148\/radiol.10092000","DOI":"10.1148\/radiol.10092000"},{"key":"ref057","doi-asserted-by":"crossref","unstructured":"57. Mehran R Nikolsky E Contrast-induced nephropathy: definition, epidemiology, and patients at risk. doi: 2006 10.1038\/sj.ki.5000368 Kidney Int Suppl: 11 5 10.1038\/sj.ki.5000368","DOI":"10.1038\/sj.ki.5000368"},{"key":"ref058","doi-asserted-by":"crossref","unstructured":"58. Dong M Jiao Z Liu T Guo F Li G Effect of administration route on the renal safety of contrast agents: a meta-analysis of randomized controlled trials 2012 J Nephrol 25 290 301 10.5301\/jn.5000067","DOI":"10.5301\/jn.5000067"},{"key":"ref059","doi-asserted-by":"crossref","unstructured":"59. Gleeson T G Bulugahapitiya S Contrast-induced nephropathy 2004 AJR Am J Roentgenol 183 1673 89 10.2214\/ajr.183.6.01831673","DOI":"10.2214\/ajr.183.6.01831673"},{"key":"ref060","doi-asserted-by":"crossref","unstructured":"60. Byrd L Sherman R L Radiocontrast-induced acute renal failure: a clinical and pathophysiologic review 1979 Medicine (Baltimore) 58 270 9","DOI":"10.1097\/00005792-197905000-00006"},{"key":"ref061","unstructured":"61. Campbell D R Flemming B K Mason W F Jackson S A Hirsch D J MacDonald K J A comparative study of the nephrotoxicity of iohexol, iopamidol and ioxaglate in peripheral angiography 1990 Can Assoc Radiol J 41 133 7"},{"key":"ref062","doi-asserted-by":"crossref","unstructured":"62. Gomes A S Baker J D Martin-Paredero V Dixon S M Takiff H Machleder H I Moore W S Acute renal dysfunction after major arteriography 1985 AJR Am J Roentgenol 145 1249 53 10.2214\/ajr.145.6.1249","DOI":"10.2214\/ajr.145.6.1249"},{"key":"ref063","doi-asserted-by":"crossref","unstructured":"63. Harkonen S Kjellstrand C Contrast nephropathy 1981 Am J Nephrol 1 69 77","DOI":"10.1159\/000166493"},{"key":"ref064","doi-asserted-by":"crossref","unstructured":"64. Katzberg R W Barrett B J Risk of iodinated contrast material--induced nephropathy with intravenous administration 2007 Radiology 243 622 8 10.1148\/radiol.2433061411","DOI":"10.1148\/radiol.2433061411"},{"key":"ref065","doi-asserted-by":"crossref","unstructured":"65. Khoury G A Hopper J C Varghese Z Farrington K Dick R Irving J D Sweny P Fernando O N Moorhead J F Nephrotoxicity of ionic and non-ionic contrast material in digital vascular imaging and selective renal arteriography 1983 Br J Radiol 56 631 5","DOI":"10.1259\/0007-1285-56-669-631"},{"key":"ref066","doi-asserted-by":"crossref","unstructured":"66. Moore R D Steinberg E P Powe N R Brinker J A Fishman E K Graziano S Gopalan R Nephrotoxicity of high-osmolality versus low-osmolality contrast media: randomized clinical trial 1992 Radiology 182 649 55","DOI":"10.1148\/radiology.182.3.1535876"},{"key":"ref067","doi-asserted-by":"crossref","unstructured":"67. Deray G Dubois M Martinez F Baumelou B Beaufils H Bourbouze R Baumelou A Jacobs C Renal effects of radiocontrast agents in rats: a new model of acute renal failure 1990 Am J Nephrol 10 507 13","DOI":"10.1159\/000168177"},{"key":"ref068","doi-asserted-by":"crossref","unstructured":"68. Bruce R J Djamali A Shinki K Michel S J Fine J P Pozniak M A Background fluctuation of kidney function versus contrast-induced nephrotoxicity 2009 AJR Am J Roentgenol 192 711 8 10.2214\/AJR.08.1413","DOI":"10.2214\/AJR.08.1413"},{"key":"ref069","doi-asserted-by":"crossref","unstructured":"69. Davenport M S Khalatbari S Dillman J R Cohan R H Caoili E M Ellis J H Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material 2013 Radiology 267 94 105 10.1148\/radiol.12121394","DOI":"10.1148\/radiol.12121394"},{"key":"ref070","doi-asserted-by":"crossref","unstructured":"70. Andreucci M Faga T Pisani A Sabbatini M Michael A Pathogenesis of Acute Renal Failure induced by iodinated radiographic contrast media 2014 Austin J Nephrol Hypertens.id1005 1 1 6","DOI":"10.1155\/2014\/691623"},{"key":"ref071","doi-asserted-by":"crossref","unstructured":"71. Katzberg R W Morris T W Schulman G Faillace R T Boylan L M Foley M J Spataro R F Fischer H W Reactions to intravenous contrast media. Part I: Severe and fatal cardiovascular reactions in a canine dehydration model 1983 Radiology 147 327 30 10.1148\/radiology.147.2.6836112","DOI":"10.1148\/radiology.147.2.6836112"},{"key":"ref072","doi-asserted-by":"crossref","unstructured":"72. Murphy S W Barrett B J Parfrey P S Contrast nephropathy 2000 J Am Soc Nephrol 11 177 82","DOI":"10.1681\/ASN.V111177"},{"key":"ref073","doi-asserted-by":"crossref","unstructured":"73. Detrenis S Meschi M Musini S Savazzi G Lights and shadows on the pathogenesis of contrast-induced nephropathy: state of the art 2005 Nephrol Dial Transplant 20 1542 50 10.1093\/ndt\/gfh868","DOI":"10.1093\/ndt\/gfh868"},{"key":"ref074","doi-asserted-by":"crossref","unstructured":"74. Heyman S N Rosen S Rosenberger C Renal parenchymal hypoxia, hypoxia adaptation, and the pathogenesis of radiocontrast nephropathy 2008 Clin J Am Soc Nephrol 3 288 96 10.2215\/CJN.02600607","DOI":"10.2215\/CJN.02600607"},{"key":"ref075","doi-asserted-by":"crossref","unstructured":"75. Andreucci M Side effects of radiographic contrast media. doi: 10.1155\/2014\/872574. Biomed Res Int 2014 872574 10.1155\/2014\/872574","DOI":"10.1155\/2014\/872574"},{"key":"ref076","doi-asserted-by":"crossref","unstructured":"76. Andreucci M Faga T Pisani A Sabbatini M Michael A Acute Kidney Injury by Radiographic Contrast Media: Pathogenesis and Prevention. doi: 10.1155\/2014\/362725. BioMed Research Int 2014 362725 10.1155\/2014\/362725","DOI":"10.1155\/2014\/362725"},{"key":"ref077","doi-asserted-by":"crossref","unstructured":"77. Sendeski M Patzak A Pallone T L Cao C Persson A E Persson P B Iodixanol, constriction of medullary descending vasa recta, and risk for contrast medium-induced nephropathy 2009 Radiology 251 697 704 10.1148\/radiol.2513081732","DOI":"10.1148\/radiol.2513081732"},{"key":"ref078","doi-asserted-by":"crossref","unstructured":"78. Giaccia A J Simon M C Johnson R The biology of hypoxia: the role of oxygen sensing in development, normal function, and disease 2004 Genes Dev 18 2183 94 10.1101\/gad.1243304","DOI":"10.1101\/gad.1243304"},{"key":"ref079","doi-asserted-by":"crossref","unstructured":"79. Sabbatini M Santillo M Pisani A Paterno R Uccello F Seru R Matrone G Spagnuolo G Andreucci M Serio V Esposito P Cianciaruso B Fuiano G Avvedimento E V Inhibition of Ras\/ERK1\/2 signaling protects against postischemic renal injury 2006 Am J Physiol Renal Physiol 290 1408 15 10.1152\/ajprenal.00304.2005","DOI":"10.1152\/ajprenal.00304.2005"},{"key":"ref080","doi-asserted-by":"crossref","unstructured":"80. Heyman S N Rosen S Khamaisi M Idee J M Rosenberger C Reactive oxygen species and the pathogenesis of radiocontrast-induced nephropathy 2010 Invest Radiol 45 188 95 10.1097\/RLI.0b013e3181d2eed8","DOI":"10.1097\/RLI.0b013e3181d2eed8"},{"key":"ref081","doi-asserted-by":"crossref","unstructured":"81. Dawson P Becker A Holton J M The effect of contrast media on the growth of bacteria 1983 Br J Radiol 56 809 15","DOI":"10.1259\/0007-1285-56-671-809"},{"key":"ref082","doi-asserted-by":"crossref","unstructured":"82. Pisani A Riccio E Andreucci M Faga T Ashour M A Di Nuzzi Mancini A Sabbatini M Role of reactive oxygen species in pathogenesis of radiocontrast-induced nephropathy. Biomed Res Int 2013 868321 10 10.1155\/2013\/868321","DOI":"10.1155\/2013\/868321"},{"key":"ref083","doi-asserted-by":"crossref","unstructured":"83. Pacher P Beckman J S Liaudet L Nitric oxide and peroxynitrite in health and disease 2007 Physiol Rev 87 315 424 10.1152\/physrev.00029.2006","DOI":"10.1152\/physrev.00029.2006"},{"key":"ref084","doi-asserted-by":"crossref","unstructured":"84. Pisani A Sabbatini M Riccio E Rossano R Andreucci M Capasso C V De Luca Carginale V Bizzarri M Borrelli A Schiattarella A Santangelo M Mancini A Effect of a recombinant manganese superoxide dismutase on prevention of contrast-induced acute kidney injury 2014 Clin Exp Nephrol 18 424 31 10.1007\/s10157-013-0828-2","DOI":"10.1007\/s10157-013-0828-2"},{"key":"ref085","doi-asserted-by":"crossref","unstructured":"85. Martin-Mateo M C Sanchez-Portugal M Iglesias S A de Paula Bustamante J Oxidative stress in chronic renal failure 1999 Ren Fail 21 155 67","DOI":"10.3109\/08860229909066980"},{"key":"ref086","doi-asserted-by":"crossref","unstructured":"86. Okamura D M Pennathur S Pasichnyk K Lopez-Guisa J M Collins S Febbraio M Heinecke J Eddy A A CD36 regulates oxidative stress and inflammation in hypercholesterolemic CKD 2009 J Am Soc Nephrol 20 495 505 10.1681\/ASN.2008010009","DOI":"10.1681\/ASN.2008010009"},{"key":"ref087","doi-asserted-by":"crossref","unstructured":"87. Gospos C Freudenberg N Staubesand J Mathias K Papacharlampos X The effect of contrast media on the aortic endothelium of rats 1983 Radiology 147 685 8 10.1148\/radiology.147.3.6844605","DOI":"10.1148\/radiology.147.3.6844605"},{"key":"ref088","doi-asserted-by":"crossref","unstructured":"88. Heyman S N Clark B A Kaiser N Spokes K Rosen S Brezis M Epstein F H Radiocontrast agents induce endothelin release in vivo and in vitro 1992 J Am Soc Nephrol 3 58 65","DOI":"10.1681\/ASN.V3158"},{"key":"ref089","doi-asserted-by":"crossref","unstructured":"89. Caiazza A Russo L Sabbatini M Russo D Hemodynamic and tubular changes induced by contrast media. doi: 10.1155\/2014\/578974. Biomed Res Int 2014 578974 10.1155\/2014\/578974","DOI":"10.1155\/2014\/578974"},{"key":"ref090","doi-asserted-by":"crossref","unstructured":"90. Hardiek K Katholi R E Ramkumar V Deitrick C Proximal tubule cell response to radiographic contrast media 2001 Am J Physiol Renal Physiol 280 61 70","DOI":"10.1152\/ajprenal.2001.280.1.F61"},{"key":"ref091","doi-asserted-by":"crossref","unstructured":"91. Michael A Faga T Pisani A Riccio E Bramanti P Sabbatini M Navarra M Andreucci M Molecular mechanisms of renal cellular nephrotoxicity due to radiocontrast media. Biomed Res Int 2014 249810 10 10.1155\/2014\/249810","DOI":"10.1155\/2014\/249810"},{"key":"ref092","doi-asserted-by":"crossref","unstructured":"92. Andreucci M Michael A Kramers C Park K M Chen A Matthaeus T Alessandrini A Haq S Force T Bonventre J V Renal ischemia\/reperfusion and ATP depletion\/repletion in LLC-PK(1) cells result in phosphorylation of FKHR and FKHRL1 2003 Kidney Int 64 1189 98","DOI":"10.1046\/j.1523-1755.2003.00204.x"},{"key":"ref093","doi-asserted-by":"crossref","unstructured":"93. Andreucci M Faga T Michael A Fuiano G Presta P Lucisano G Leone F Fuiano L Bisesti V Esposito P Russo D Memoli B Downregulation of cell survival signalling pathways and increased cell damage in hydrogen peroxide-treated human renal proximal tubular cells by alpha-erythropoietin 2009 Cell Prolif 42 554 61","DOI":"10.1111\/j.1365-2184.2009.00617.x"},{"key":"ref094","unstructured":"94. Andreucci M [Contrast media and nephrotoxicity: a molecular conundrum] 2011 G Ital Nefrol 28 355"},{"key":"ref095","doi-asserted-by":"crossref","unstructured":"95. Pisani A Sabbatini M Salzano S Vitale M Fuiano G Michael A Andreucci M Lucisano G Faga T Bertucci B Tamburrini O Differential activation of signaling pathways involved in cell death, survival and inflammation by radiocontrast media in human renal proximal tubular cells 2011 Toxicol Sci 119 408 16 10.1093\/toxsci\/kfq332","DOI":"10.1093\/toxsci\/kfq332"},{"key":"ref096","doi-asserted-by":"crossref","unstructured":"96. Andreucci M Fuiano G Presta P Esposito P Faga T Bisesti V Procino A Altieri V Tozzo C Memoli B Michael A Radiocontrast media cause dephosphorylation of Akt and downstream signaling targets in human renal proximal tubular cells 2006 Biochem Pharmacol 72 1334 42","DOI":"10.1016\/j.bcp.2006.08.008"},{"key":"ref097","doi-asserted-by":"crossref","unstructured":"97. Andreucci M Fuiano G Michael A Faga T Russo D Bertucci B Tamburrini O Pisani A Sabbatini M Differential activation of signaling pathways by low-osmolar and iso-osmolar radiocontrast agents in human renal tubular cells 2014 J Cell Biochem 115 281 9 10.1002\/jcb.24662","DOI":"10.1002\/jcb.24662"},{"key":"ref098","doi-asserted-by":"crossref","unstructured":"98. Dawson P Pitfield J Skinnemoen K Isomeric purity and supersaturation of iopamidol 1983 Br J Radiol 56 711 3","DOI":"10.1259\/0007-1285-56-670-711"},{"key":"ref099","doi-asserted-by":"crossref","unstructured":"99. Andreucci M Faga T Lucisano G Uccello F Pisani A Memoli B Sabbatini M Fuiano G Michael A Mycophenolic acid inhibits the phosphorylation of NF-kappaB and JNKs and causes a decrease in IL-8 release in H2O2-treated human renal proximal tubular cells 2010 Chem Biol Interact 185 253 62 10.1016\/j.cbi.2010.03.019","DOI":"10.1016\/j.cbi.2010.03.019"},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"100. Cunha M A Schor N Effects of gentamicin, lipopolysaccharide, and contrast media on immortalized proximal tubular cells 2002 Ren Fail 24 687 90","DOI":"10.1081\/JDI-120015662"},{"key":"ref101","doi-asserted-by":"crossref","unstructured":"101. Peer A Averbukh Z Berman S Modai D Averbukh M Weissgarten J Contrast media augmented apoptosis of cultured renal mesangial, tubular, epithelial, endothelial, and hepatic cells 2003 Invest Radiol 38 177 82 10.1097\/01.RLI.0000054529.61167.84","DOI":"10.1097\/01.RLI.0000054529.61167.84"},{"key":"ref102","doi-asserted-by":"crossref","unstructured":"102. Yang D Yang D Jia R Tan J Na+\/Ca2+ exchange inhibitor, KB-R7943, attenuates contrast-induced acute kidney injury 2013 J Nephrol 26 877 85 10.5301\/jn.5000259","DOI":"10.5301\/jn.5000259"},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"103. Duan S B Liu F Y Luo J A Wu H W Liu R H Peng Y M Yang X L Nephrotoxicity of high- and low-osmolar contrast media. The protective role of amlodipine in a rat model 2000 Acta Radiol 41 503 7","DOI":"10.1080\/028418500127345794"},{"key":"ref104","unstructured":"104. Aspelin P Nilsson P E Schmid-Schonbein H Schroder S Simon R Effect of four non-ionic contrast media on red blood cells in vitro 1987 III. Deformability. Acta Radiol Suppl 370 89 91"},{"key":"ref105","doi-asserted-by":"crossref","unstructured":"105. Hardeman M R Goedhart P Koen I Y The effect of low-osmolar ionic and nonionic contrast media on human blood viscosity, erythrocyte morphology, and aggregation behavior 1991 Invest Radiol 26 810 9","DOI":"10.1097\/00004424-199109000-00006"},{"key":"ref106","doi-asserted-by":"crossref","unstructured":"106. Franke R P Scharnweber T Fuhrmann R Wenzel F Kruger A Mrowietz C Jung F Effect of radiographic contrast media on the spectrin\/band3-network of the membrane skeleton of erythrocytes. doi: 10.1371\/journal.pone.0089512. PLoS One 9: 2014 89512 10.1371\/journal.pone.0089512","DOI":"10.1371\/journal.pone.0089512"},{"key":"ref107","doi-asserted-by":"crossref","unstructured":"107. Thomsen H S Guidelines for contrast media from the European Society of Urogenital Radiology 2003 AJR Am J Roentgenol 181 1463 71 10.2214\/ajr.181.6.1811463","DOI":"10.2214\/ajr.181.6.1811463"},{"key":"ref108","doi-asserted-by":"crossref","unstructured":"108. Andreucci V E Russo D Cianciaruso B Andreucci M Some sodium, potassium and water changes in the elderly and their treatment 1996 Nephrol Dial Transplant11Suppl 9 9 17","DOI":"10.1093\/ndt\/11.supp9.9"},{"key":"ref109","doi-asserted-by":"crossref","unstructured":"109. Neyra J A Shah S Mooney R Jacobsen G Yee J Novak J E Contrast-induced acute kidney injury following coronary angiography: a cohort study of hospitalized patients with or without chronic kidney disease 2013 Nephrol Dial Transplant 28 1463 71 10.1093\/ndt\/gft082","DOI":"10.1093\/ndt\/gft082"},{"key":"ref110","doi-asserted-by":"crossref","unstructured":"110. Toprak O Conflicting and new risk factors for contrast induced nephropathy 2007 J Urol 178 2277 83 10.1016\/j.juro.2007.08.054","DOI":"10.1016\/j.juro.2007.08.054"},{"key":"ref111","doi-asserted-by":"crossref","unstructured":"111. Toprak O Cirit M Yesil M Bayata S Tanrisev M Varol U Ersoy R Esi E Impact of diabetic and pre-diabetic state on development of contrast-induced nephropathy in patients with chronic kidney disease 2007 Nephrol Dial Transplant 22 819 26 10.1093\/ndt\/gfl636","DOI":"10.1093\/ndt\/gfl636"},{"key":"ref112","doi-asserted-by":"crossref","unstructured":"112. Schoolwerth A C Sica D A Ballermann B J Wilcox C S Council on the Kidney in Cardiovascular D. and the Council for High Blood Pressure Research of the American Heart A(2001)Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association Circulation 104 1985 91","DOI":"10.1161\/hc4101.096153"},{"key":"ref113","doi-asserted-by":"crossref","unstructured":"113. Hardiek K J Katholi R E Robbs R S Katholi C E Renal effects of contrast media in diabetic patients undergoing diagnostic or interventional coronary angiography 2008 J Diabetes Complications 22 171 7 10.1016\/j.jdiacomp.2006.11.002","DOI":"10.1016\/j.jdiacomp.2006.11.002"},{"key":"ref114","doi-asserted-by":"crossref","unstructured":"114. Pflueger A Larson T S Nath K A King B F Gross J M Knox F G Role of adenosine in contrast media-induced acute renal failure in diabetes mellitus 2000 Mayo Clin Proc 75 1275 83 10.4065\/75.12.1275","DOI":"10.4065\/75.12.1275"},{"key":"ref115","doi-asserted-by":"crossref","unstructured":"115. Khamaisi M Raz I Shilo V Shina A Rosenberger C Dahan R Abassi Z Meidan R Lecht S Heyman S N Diabetes and radiocontrast media increase endothelin converting enzyme-1 in the kidney 2008 Kidney Int 74 91 100 10.1038\/ki.2008.112","DOI":"10.1038\/ki.2008.112"},{"key":"ref116","doi-asserted-by":"crossref","unstructured":"116. Rudnick M R Goldfarb S Tumlin J Contrast-induced nephropathy: is the picture any clearer? 2008 Clin J Am Soc Nephrol 3 261 2 10.2215\/CJN.04951107","DOI":"10.2215\/CJN.04951107"},{"key":"ref117","doi-asserted-by":"crossref","unstructured":"117. Morabito S Pistolesi V Benedetti G A Di Roma Colantonio R Mancone M Sardella G Cibelli L Ambrosino M Polistena F Pierucci A Incidence of contrast-induced acute kidney injury associated with diagnostic or interventional coronary angiography 2012 J Nephrol 25 1098 107 10.5301\/jn.5000101","DOI":"10.5301\/jn.5000101"},{"key":"ref118","doi-asserted-by":"crossref","unstructured":"118. Morcos S K Contrast media-induced nephrotoxicity--questions and answers 1998 Br J Radiol 71 357 65","DOI":"10.1259\/bjr.71.844.9659127"},{"key":"ref119","doi-asserted-by":"crossref","unstructured":"119. Kolonko A Kokot F Wiecek A Contrast-associated nephropathy--old clinical problem and new therapeutic perspectives 1998 Nephrol Dial Transplant 13 803 6","DOI":"10.1093\/ndt\/13.3.803"},{"key":"ref120","doi-asserted-by":"crossref","unstructured":"120. Yang D Lin S Yang D Wei L Shang W Effects of short- and long-term hypercholesterolemia on contrast-induced acute kidney injury 2012 Am J Nephrol 35 80 9 10.1159\/000335077","DOI":"10.1159\/000335077"},{"key":"ref121","doi-asserted-by":"crossref","unstructured":"121. Pahade J K LeBedis C A Raptopoulos V D Avigan D E Yam C S Kruskal J B Pedrosa I Incidence of contrast-induced nephropathy in patients with multiple myeloma undergoing contrast-enhanced CT 2011 AJR Am J Roentgenol 196 1094 101 10.2214\/AJR.10.5152","DOI":"10.2214\/AJR.10.5152"},{"key":"ref122","doi-asserted-by":"crossref","unstructured":"122. Andreucci M Faga T Sabbatini M Pisani A Russo D Michael A How to prevent Contrast-Induced Nephropathy in clinical practice 2014 J Clin Nephrol Res 1 1002","DOI":"10.1155\/2014\/691623"},{"key":"ref123","doi-asserted-by":"crossref","unstructured":"123. Keaney J J Hannon C M Murray P T Contrast-induced acute kidney injury: how much contrast is safe? 2013 Nephrol Dial Transplant 28 1376 83 10.1093\/ndt\/gfs602","DOI":"10.1093\/ndt\/gfs602"},{"key":"ref124","doi-asserted-by":"crossref","unstructured":"124. Cigarroa R G Lange R A Williams R H Hillis L D Dosing of contrast material to prevent contrast nephropathy in patients with renal disease 1989 Am J Med 86 649 52","DOI":"10.1016\/0002-9343(89)90437-3"},{"key":"ref125","doi-asserted-by":"crossref","unstructured":"125. Laskey W K Jenkins C Selzer F Marroquin O C Wilensky R L Glaser R Cohen H A Holmes D R and Investigators NDR(2007)Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention J Am Coll Cardiol 50 584 90 10.1016\/j.jacc.2007.03.058","DOI":"10.1016\/j.jacc.2007.03.058"},{"key":"ref126","doi-asserted-by":"crossref","unstructured":"126. Gurm H S Dixon S R Smith D E Share D Lalonde T Greenbaum A Moscucci M BMC Registry Renal function-based contrast dosing to define safe limits of radiographic contrast media in patients undergoing percutaneous coronary interventions 2011 J Am Coll Cardiol 58 907 14 10.1016\/j.jacc.2011.05.023","DOI":"10.1016\/j.jacc.2011.05.023"},{"key":"ref127","doi-asserted-by":"crossref","unstructured":"127. Mueller C Prevention of contrast-induced nephropathy with volume supplementation. doi: 10.1038\/sj.ki.5000369. Kidney Int Suppl:S16-9 2006 10.1038\/sj.ki.5000369","DOI":"10.1038\/sj.ki.5000369"},{"key":"ref128","doi-asserted-by":"crossref","unstructured":"128. Balemans C E Reichert L J van Schelven BI JA van den Brand Wetzels J F Epidemiology of contrast material-induced nephropathy in the era of hydration 2012 Radiology 263 706 13 10.1148\/radiol.12111667129","DOI":"10.1148\/radiol.12111667"},{"key":"ref129","doi-asserted-by":"crossref","unstructured":"129. Andreucci M Faga T Pisani A Sabbatini M Russo D Michael A Prevention of Contrast-Induced Nephropathy through a knowledge of its pathogenesis and risk factors. doi: 10.1155\/2014\/823169 Scientific Worl dJournal; 2014 823169 10.1155\/2014\/823169","DOI":"10.1155\/2014\/823169"},{"key":"ref130","doi-asserted-by":"crossref","unstructured":"130. Solomon R Dauerman H L Contrast-induced acute kidney injury 2010 Circulation 122 2451 5 10.1161\/CIRCULATIONAHA.110.953851","DOI":"10.1161\/CIRCULATIONAHA.110.953851"},{"key":"ref131","doi-asserted-by":"crossref","unstructured":"131. Merten G J Burgess W P Gray L V Holleman J H Roush T S Kowalchuk G J Bersin R M A Van Moore Simonton C A Rittase RA 3rd Norton H J Kennedy T P Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial 2004 JAMA 291 2328 34 10.1001\/jama.291.19.2328","DOI":"10.1001\/jama.291.19.2328"},{"key":"ref132","doi-asserted-by":"crossref","unstructured":"132. Masuda M Yamada T Mine T Morita T Tamaki S Tsukamoto Y Okuda K Iwasaki Y Hori M Fukunami M Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure 2007 Am J Cardiol 100 781 6 10.1016\/j.amjcard.2007.03.098","DOI":"10.1016\/j.amjcard.2007.03.098"},{"key":"ref133","doi-asserted-by":"crossref","unstructured":"133. Ozcan E E Guneri S Akdeniz B Akyildiz I Z Senaslan O Baris N Aslan O Badak O Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial 2007 Am Heart J 154 539 44 10.1016\/j.ahj.2007.05.012","DOI":"10.1016\/j.ahj.2007.05.012"},{"key":"ref134","doi-asserted-by":"crossref","unstructured":"134. Tamura A Goto Y Miyamoto K Naono S Kawano Y Kotoku M Watanabe T Kadota J Efficacy of single-bolus administration of sodium bicarbonate to prevent contrast-induced nephropathy in patients with mild renal insufficiency undergoing an elective coronary procedure 2009 Am J Cardiol 104 921 5 10.1016\/j.amjcard.2009.05.034","DOI":"10.1016\/j.amjcard.2009.05.034"},{"key":"ref135","doi-asserted-by":"crossref","unstructured":"135. Navaneethan S D Singh S Appasamy S Wing R E Sehgal A R Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis 2009 Am J Kidney Dis 53 617 27 10.1053\/j.ajkd.2008.08.033","DOI":"10.1053\/j.ajkd.2008.08.033"},{"key":"ref136","doi-asserted-by":"crossref","unstructured":"136. Hoste E A De Waele JJ Gevaert S A Uchino S Kellum J A Sodium bicarbonate for prevention of contrast-induced acute kidney injury: a systematic review and meta-analysis 2010 Nephrol Dial Transplant 25 747 58 10.1093\/ndt\/gfp389","DOI":"10.1093\/ndt\/gfp389"},{"key":"ref137","doi-asserted-by":"crossref","unstructured":"137. Joannidis M Schmid M Wiedermann C J Prevention of contrast media-induced nephropathy by isotonic sodium bicarbonate: a meta-analysis 2008 Wien Klin Wochenschr 120 742 8 10.1007\/s00508-008-1117-z","DOI":"10.1007\/s00508-008-1117-z"},{"key":"ref138","doi-asserted-by":"crossref","unstructured":"138. Assadi F Acetazolamide for prevention of contrast-induced nephropathy: a new use for an old drug 2006 Pediatr Cardiol 27 238 42 10.1007\/s00246-005-1132-z","DOI":"10.1007\/s00246-005-1132-z"},{"key":"ref139","doi-asserted-by":"crossref","unstructured":"139. Pakfetrat M Nikoo M H Malekmakan L Tabandeh M Roozbeh J Nasab M H Ostovan M A Salari S Kafi M Vaziri N M Adl F Hosseini M Khajehdehi P A comparison of sodium bicarbonate infusion versus normal saline infusion and its combination with oral acetazolamide for prevention of contrast-induced nephropathy: a randomized, double-blind trial 2009 Int Urol Nephrol 41 629 34 10.1007\/s11255-008-9520-y","DOI":"10.1007\/s11255-008-9520-y"},{"key":"ref140","unstructured":"140. Reddan D Laville M Garovic V D Contrast-induced nephropathy and its prevention: What do we really know from evidence-based findings? 2009 J Nephrol 22 333 51"},{"key":"ref141","doi-asserted-by":"crossref","unstructured":"141. Zoungas S Ninomiya T Huxley R Cass A Jardine M Gallagher M Patel A Vasheghani-Farahani A Sadigh G Perkovic V Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy 2009 Ann Intern Med 151 631 8 10.7326\/0003-4819-151-9-200911030-00008","DOI":"10.7326\/0003-4819-151-9-200911030-00008"},{"key":"ref142","doi-asserted-by":"crossref","unstructured":"142. Brar S S Shen A Y Jorgensen M B Kotlewski A Aharonian V J Desai N Ree M Shah A I Burchette R J Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial 2008 JAMA 300 1038 46 10.1001\/jama.300.9.1038","DOI":"10.1001\/jama.300.9.1038"},{"key":"ref143","doi-asserted-by":"crossref","unstructured":"143. Brar S S Hiremath S Dangas G Mehran R Brar S K Leon M B Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and meta-analysis 2009 Clin J Am Soc Nephrol 4 1584 92 10.2215\/CJN.03120509","DOI":"10.2215\/CJN.03120509"},{"key":"ref144","doi-asserted-by":"crossref","unstructured":"144. Shavit L Korenfeld R Lifschitz M Butnaru A Slotki I Sodium bicarbonate versus sodium chloride and oral N-acetylcysteine for the prevention of contrast-induced nephropathy in advanced chronic kidney disease 2009 J Interv Cardiol 22 556 63 10.1111\/j.1540-8183.2009.00500.x","DOI":"10.1111\/j.1540-8183.2009.00500.x"},{"key":"ref145","doi-asserted-by":"crossref","unstructured":"145. Vasheghani-Farahani A Sadigh G Kassaian S E Khatami S M Fotouhi A Razavi S A Mansournia M A Yamini-Sharif A Amirzadegan A Salarifar M Sadeghian S Davoodi G Borumand M A Sodium bicarbonate plus isotonic saline versus saline for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: a randomized controlled trial 2009 Am J Kidney Dis Esfehani FA and Darabian S 54 610 8 10.1053\/j.ajkd.2009.05.016","DOI":"10.1053\/j.ajkd.2009.05.016"},{"key":"ref146","doi-asserted-by":"crossref","unstructured":"146. From A M Bartholmai B J Williams A W Cha S S Pflueger A McDonald F S Sodium bicarbonate is associated with an increased incidence of contrast nephropathy: a retrospective cohort study of 7977 patients at mayo clinic 2008 Clin J Am Soc Nephrol 3 10 8 10.2215\/CJN.03100707","DOI":"10.2215\/CJN.03100707"},{"key":"ref147","doi-asserted-by":"crossref","unstructured":"147. Brar S S Aharonian V Mansukhani P Moore N Shen A Y Jorgensen M Dua A Short L Kane K Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial 2014 Lancet 383 1814 23 10.1016\/S0140-6736(14)60689-9","DOI":"10.1016\/S0140-6736(14)60689-9"},{"key":"ref148","doi-asserted-by":"crossref","unstructured":"148. Fliser D Laville M Covic A Fouque D Vanholder R Juillard L W Van Biesen Ad-hoc working group of E(2012)A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy Nephrol Dial Transplant 27 4263 72 10.1093\/ndt\/gfs375","DOI":"10.1093\/ndt\/gfs375"},{"key":"ref149","doi-asserted-by":"crossref","unstructured":"149. Sardella G Briguori C Garbo R Romagnoli E Pennacchi M Donahue M Boccuzzi G Summaria F Conti G Canali E Placentino F Stio R Lucisano L Biondi-Zoccai G Mancone M Fedele F Evidence from the Resorbable-polymer stent versus Unresorbable-polymer stent Deployment for coronary Intervention: (RUDI-2) registry. doi: 10.1016\/j.ijcard.2013.12.220 2014 Int J Cardiol 10.1016\/j.ijcard.2013.12.220","DOI":"10.1016\/j.ijcard.2013.12.220"},{"key":"ref150","doi-asserted-by":"crossref","unstructured":"150. Lee H C Sheu S H Liu I H Lee C C Hsieh C C Yen H W Lai W T Chang J G Impact of short-duration administration of N-acetylcysteine, probucol and ascorbic acid on contrast-induced cytotoxicity 2012 J Nephrol 25 56 62 10.5301\/JN.2011.7741","DOI":"10.5301\/JN.2011.7741"},{"key":"ref151","doi-asserted-by":"crossref","unstructured":"151. DiMari J Megyesi J Udvarhelyi N Price P Davis R Safirstein R N-acetyl cysteine ameliorates ischemic renal failure 1997 Am J Physiol 272 292 8","DOI":"10.1152\/ajprenal.1997.272.3.F292"},{"key":"ref152","doi-asserted-by":"crossref","unstructured":"152. Baker C S Wragg A Kumar S R De Palma Baker L R Knight C J A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study 2003 J Am Coll Cardiol 41 2114 8","DOI":"10.1016\/S0735-1097(03)00487-X"},{"key":"ref153","doi-asserted-by":"crossref","unstructured":"153. Tepel M Giet M van der Schwarzfeld C Laufer U Liermann D Zidek W Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine 2000 N Engl J Med 343 180 4 10.1056\/NEJM200007203430304","DOI":"10.1056\/NEJM200007203430304"},{"key":"ref154","doi-asserted-by":"crossref","unstructured":"154. Briguori C Colombo A Violante A Balestrieri P Manganelli F Paolo Elia P Golia B Lepore S Riviezzo G Scarpato P Focaccio A Librera M Bonizzoni E Ricciardelli B Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity 2004 Eur Heart J 25 206 11 10.1016\/j.ehj.2003.11.016","DOI":"10.1016\/j.jacc.2004.04.052"},{"key":"ref155","doi-asserted-by":"crossref","unstructured":"155. Durham J D Caputo C Dokko J Zaharakis T Pahlavan M Keltz J Dutka P Marzo K Maesaka J K Fishbane S A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography 2002 Kidney Int 62 2202 7 10.1046\/j.1523-1755.2002.00673.x","DOI":"10.1046\/j.1523-1755.2002.00673.x"},{"key":"ref156","doi-asserted-by":"crossref","unstructured":"156. Allaqaband S Tumuluri R Malik A M Gupta A Volkert P Shalev Y Bajwa T K Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy 2002 Catheter Cardiovasc Interv 57 279 83 10.1002\/ccd.10323","DOI":"10.1002\/ccd.10323"},{"key":"ref157","doi-asserted-by":"crossref","unstructured":"157. Goldenberg I Shechter M Matetzky S Jonas M Adam M Pres H Elian D Agranat O Schwammenthal E Guetta V Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature 2004 Eur Heart J 25 212 8 10.1016\/j.ehj.2003.11.011","DOI":"10.1016\/j.ehj.2003.11.011"},{"key":"ref158","doi-asserted-by":"crossref","unstructured":"158. Panzer C Beazley R Braverman L Rapid preoperative preparation for severe hyperthyroid Graves' disease 2004 J Clin Endocrinol Metab 89 2142 4","DOI":"10.1210\/jc.2003-031981"},{"key":"ref159","doi-asserted-by":"crossref","unstructured":"159. Coyle L C Rodriguez A Jeschke R E Simon-Lee A Abbott K C Taylor A J Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics 2006 Am Heart J 151 1032 9 12 10.1016\/j.ahj.2006.02.002","DOI":"10.1016\/j.ahj.2006.02.002"},{"key":"ref160","doi-asserted-by":"crossref","unstructured":"160. Ferrario F Barone M T Landoni G Genderini A Heidemperger M Trezzi M Piccaluga E Danna P Scorza D Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy--a randomized controlled study 2009 Nephrol Dial Transplant 24 3103 7 10.1093\/ndt\/gfp306","DOI":"10.1093\/ndt\/gfp306"},{"key":"ref161","doi-asserted-by":"crossref","unstructured":"161. Gurm H S Smith D E Berwanger O Share D Schreiber T Moscucci M Nallamothu B K Bmc Contemporary use and effectiveness of N-acetylcysteine in preventing contrast-induced nephropathy among patients undergoing percutaneous coronary intervention 2012 JACC Cardiovasc Interv 5 98 104 10.1016\/j.jcin.2011.09.019","DOI":"10.1016\/j.jcin.2011.09.019"},{"key":"ref162","doi-asserted-by":"crossref","unstructured":"162. Spargias K Alexopoulos E Kyrzopoulos S Iokovis P Greenwood D C Manginas A Voudris V Pavlides G Buller C E Kremastinos D Cokkinos D V Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention 2004 Circulation 110 2837 42 10.1161\/01.CIR.0000146396.19081.73","DOI":"10.1161\/01.CIR.0000146396.19081.73"},{"key":"ref163","doi-asserted-by":"crossref","unstructured":"163. Alexopoulos E Spargias K Kyrzopoulos S Manginas A Pavlides G Voudris V Lerakis S McLean D S Cokkinos D V Contrast-induced acute kidney injury in patients with renal dysfunction undergoing a coronary procedure and receiving non-ionic low-osmolar versus iso-osmolar contrast media 2010 Am J Med Sci 339 25 30 10.1097\/MAJ.0b013e3181c06e70","DOI":"10.1097\/MAJ.0b013e3181c06e70"},{"key":"ref164","doi-asserted-by":"crossref","unstructured":"164. Boscheri A Weinbrenner C Botzek B Reynen K Kuhlisch E Strasser R H Failure of ascorbic acid to prevent contrast-media induced nephropathy in patients with renal dysfunction 2007 Clin Nephrol 68 279 86","DOI":"10.5414\/CNP68279"},{"key":"ref165","doi-asserted-by":"crossref","unstructured":"165. Jo S H Koo B K Park J S Kang H J Kim Y J Kim H L Chae I H Choi D J Sohn D W Oh B H Park Y B Choi Y S Kim H S N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial 2009 Am Heart J 157 576 83 10.1016\/j.ahj.2008.11.010","DOI":"10.1016\/j.ahj.2008.11.010"},{"key":"ref166","doi-asserted-by":"crossref","unstructured":"166. Dvorsak B Kanic V Ekart R Bevc S Hojs R Ascorbic Acid for the prevention of contrast-induced nephropathy after coronary angiography in patients with chronic renal impairment: a randomized controlled trial 2013 Ther Apher Dial 17 384 90 10.1111\/1744-9987.12083","DOI":"10.1111\/1744-9987.12083"},{"key":"ref167","doi-asserted-by":"crossref","unstructured":"167. Sadat U Usman A Gillard J H Boyle J R Does ascorbic acid protect against contrast-induced acute kidney injury in patients undergoing coronary angiography: a systematic review with meta-analysis of randomized, controlled trials 2013 J Am Coll Cardiol 62 2167 75 10.1016\/j.jacc.2013.07.065","DOI":"10.1016\/j.jacc.2013.07.065"},{"key":"ref168","doi-asserted-by":"crossref","unstructured":"168. Tasanarong A Vohakiat A Hutayanon P Piyayotai D New strategy of alpha- and gamma-tocopherol to prevent contrast-induced acute kidney injury in chronic kidney disease patients undergoing elective coronary procedures 2013 Nephrol Dial Transplant 28 337 44 10.1093\/ndt\/gfs525","DOI":"10.1093\/ndt\/gfs525"},{"key":"ref169","doi-asserted-by":"crossref","unstructured":"169. Veverka A Nuzum D S Jolly J L Nebivolol: a third-generation beta-adrenergic blocker 2006 Ann Pharmacother 40 1353 60 10.1345\/aph.1G708","DOI":"10.1345\/aph.1G708"},{"key":"ref170","doi-asserted-by":"crossref","unstructured":"170. Sule S S Frishman W Nebivolol: new therapy update 2006 Cardiol Rev 14 259 64 10.1097\/01.crd.0000223651.03023.8e","DOI":"10.1097\/01.crd.0000223651.03023.8e"},{"key":"ref171","doi-asserted-by":"crossref","unstructured":"171. Toprak O Cirit M Tanrisev M Yazici C Canoz O Sipahioglu M Uzum A Ersoy R Sozmen E Y Preventive effect of nebivolol on contrast-induced nephropathy in rats 2008 Nephrol Dial Transplant 23 853 9 10.1093\/ndt\/gfm691","DOI":"10.1093\/ndt\/gfm691"},{"key":"ref172","doi-asserted-by":"crossref","unstructured":"172. Avci E Yesil M Bayata S Postaci N Arikan E Cirit M The role of nebivolol in the prevention of contrast-induced nephropathy in patients with renal dysfunction 2011 Anadolu Kardiyol Derg 11 613 7 10.5152\/akd.2011.164","DOI":"10.5152\/akd.2011.164"},{"key":"ref173","doi-asserted-by":"crossref","unstructured":"173. Gunebakmaz O Kaya M G Koc F Akpek M Kasapkara A Inanc M T Yarlioglues M Calapkorur B Karadag Z Oguzhan A Does nebivolol prevent contrast-induced nephropathy in humans? 2012 Clin Cardiol 35 250 4 10.1002\/clc.21013","DOI":"10.1002\/clc.21013"},{"key":"ref174","doi-asserted-by":"crossref","unstructured":"174. Ari E Kedrah A E Alahdab Y Bulut G Eren Z Baytekin O Odabasi D Antioxidant and renoprotective effects of paricalcitol on experimental contrast-induced nephropathy model 2012 Br J Radiol 85 1038 43 10.1259\/bjr\/16327485","DOI":"10.1259\/bjr\/16327485"},{"key":"ref175","doi-asserted-by":"crossref","unstructured":"175. Majumdar S R Kjellstrand C M Tymchak W J Hervas-Malo M Taylor D A Teo K K Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: a randomized controlled trial 2009 Am J Kidney Dis 54 602 9 10.1053\/j.ajkd.2009.03.024","DOI":"10.1053\/j.ajkd.2009.03.024"},{"key":"ref176","doi-asserted-by":"crossref","unstructured":"176. Cetin M Devrim E Serin Kilicoglu S Erguder I B Namuslu M Cetin R Durak I Ionic high-osmolar contrast medium causes oxidant stress in kidney tissue: partial protective role of ascorbic acid 2008 Ren Fail 30 567 72 10.1080\/08860220802064739","DOI":"10.1080\/08860220802064739"},{"key":"ref177","unstructured":"177. Devrim E Cetin M Namuslu M Erguder I B Cetin R Durak I Oxidant stress due to non ionic low osmolar contrast medium in rat kidney 2009 Indian J Med Res 130 433 6"},{"key":"ref178","doi-asserted-by":"crossref","unstructured":"178. Husain K Ferder L Mizobuchi M Finch J Slatopolsky E Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats 2009 Am J Nephrol 29 465 72 10.1159\/000178251","DOI":"10.1159\/000178251"},{"key":"ref179","doi-asserted-by":"crossref","unstructured":"179. Husain K Suarez E Isidro A Ferder L Effects of paricalcitol and enalapril on atherosclerotic injury in mouse aortas 2010 Am J Nephrol 32 296 304 10.1159\/000319445","DOI":"10.1159\/000319445"},{"key":"ref180","doi-asserted-by":"crossref","unstructured":"180. Park J W Bae E H Kim I J Ma S K Choi C Lee J Kim S W Paricalcitol attenuates cyclosporine-induced kidney injury in rats 2010 Kidney Int 77 1076 85 10.1038\/ki.2010.69","DOI":"10.1038\/ki.2010.69"},{"key":"ref181","doi-asserted-by":"crossref","unstructured":"181. Khanal S Attallah N Smith D E Kline-Rogers E Share D O\u2019Donnell M J Moscucci M Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions 2005 Am J Med 118 843 9 10.1016\/j.amjmed.2005.03.031","DOI":"10.1016\/j.amjmed.2005.03.031"},{"key":"ref182","doi-asserted-by":"crossref","unstructured":"182. Patti G Nusca A Chello M Pasceri V D\u2019Ambrosio A Vetrovec G W DiSciascio G Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention 2008 Am J Cardiol 101 279 85 10.1016\/j.amjcard.2007.08.030","DOI":"10.1016\/j.amjcard.2007.08.030"},{"key":"ref183","unstructured":"183. Leoncini M Toso A Maioli M Tropeano F Bellandi F Statin treatment before percutaneous cononary intervention 2013 J Thorac Dis 5 335 42 10.3978\/j.issn.2072-1439.2013.05.09"},{"key":"ref184","doi-asserted-by":"crossref","unstructured":"184. Zhang B C Li W M Xu Y W High-dose statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis 2011 Can J Cardiol 27 851 8 10.1016\/j.cjca.2011.05.005","DOI":"10.1016\/j.cjca.2011.05.005"},{"key":"ref185","unstructured":"185. Andreucci M [Statins in CIN: a problem at least partly solved?] 2013 G Ital Nefrol 30 3"},{"key":"ref186","doi-asserted-by":"crossref","unstructured":"186. Sabbatini M Pisani A Uccello F Serio V Seru R Paterno R Cianciaruso B Fuiano G Andreucci M Atorvastatin improves the course of ischemic acute renal failure in aging rats 2004 J Am Soc Nephrol 15 901 9","DOI":"10.1097\/01.ASN.0000119573.01290.AE"},{"key":"ref187","doi-asserted-by":"crossref","unstructured":"187. Al-Otaibi K E Al Elaiwi AM Tariq M Al-Asmari A K Simvastatin attenuates contrast-induced nephropathy through modulation of oxidative stress, proinflammatory myeloperoxidase, and nitric oxide. doi: 10.1155\/2012\/831748. Oxid Med Cell Longev 2012 831748 10.1155\/2012\/831748","DOI":"10.1155\/2012\/831748"},{"key":"ref188","doi-asserted-by":"crossref","unstructured":"188. Quintavalle C Fiore D F De Micco Visconti G Focaccio A Golia B Ricciardelli B Donnarumma E Bianco A Zabatta M A Troncone G Colombo A Briguori C Condorelli G Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury 2012 Circulation 126 3008 16 10.1161\/CIRCULATIONAHA.112.103317","DOI":"10.1161\/CIRCULATIONAHA.112.103317"},{"key":"ref189","doi-asserted-by":"crossref","unstructured":"189. Han Y Zhu G Han L Hou F Huang W Liu H Gan J Jiang T Li X Wang W Ding S Jia S Shen W Wang D Sun L Qiu J Wang X Li Y Deng J Li J Xu K Xu B Mehran R Huo Y Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease 2014 J Am Coll Cardiol 63 62 70 10.1016\/j.jacc.2013.09.017","DOI":"10.1016\/j.jacc.2013.09.017"},{"key":"ref190","doi-asserted-by":"crossref","unstructured":"190. Yoshida S Kamihata H Nakamura S Senoo T Manabe K Motohiro M Sugiura T Iwasaka T Prevention of contrast-induced nephropathy by chronic pravastatin treatment in patients with cardiovascular disease and renal insufficiency 2009 J Cardiol 54 10 1016 10.1016\/j.jjcc.2009.05.006","DOI":"10.1016\/j.jjcc.2009.05.006"},{"key":"ref191","doi-asserted-by":"crossref","unstructured":"191. Munoz M A Maxwell P R Green K Hughes D W Talbert R L Pravastatin versus simvastatin for prevention of contrast-induced nephropathy 2011 J Cardiovasc Pharmacol Ther 16 376 9 10.1177\/1074248410394362","DOI":"10.1177\/1074248410394362"},{"key":"ref192","doi-asserted-by":"crossref","unstructured":"192. Acikel S Muderrisoglu H Yildirir A Aydinalp A Sade E Bayraktar N Bal U Ozin B Prevention of contrast-induced impairment of renal function by short-term or long-term statin therapy in patients undergoing elective coronary angiography 2010 Blood Coagul Fibrinolysis 21 750 7 10.1097\/MBC.0b013e32834014a4","DOI":"10.1097\/MBC.0b013e32834014a4"},{"key":"ref193","doi-asserted-by":"crossref","unstructured":"193. Patti G Ricottini E Nusca A Colonna G Pasceri V D'Ambrosio A Montinaro A G Di Sciascio Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial 2011 Am J Cardiol 108 1 7 10.1016\/j.amjcard.2011.03.001","DOI":"10.1016\/j.amjcard.2011.03.001"},{"key":"ref194","doi-asserted-by":"crossref","unstructured":"194. Solomon R Werner C Mann D D\u2019Elia J Silva P Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents 1994 N Engl J Med 331 1416 20 10.1056\/NEJM199411243312104","DOI":"10.1056\/NEJM199411243312104"},{"key":"ref195","doi-asserted-by":"crossref","unstructured":"195. Weinstein J M Heyman S Brezis M Potential deleterious effect of furosemide in radiocontrast nephropathy 1992 Nephron 62 413 5","DOI":"10.1159\/000187090"},{"key":"ref196","doi-asserted-by":"crossref","unstructured":"196. Weisberg L S Kurnik P B Kurnik B R Risk of radiocontrast nephropathy in patients with and without diabetes mellitus 1994 Kidney Int 45 259 65","DOI":"10.1038\/ki.1994.32"},{"key":"ref197","doi-asserted-by":"crossref","unstructured":"197. Briguori C Visconti G Focaccio A Airoldi F Valgimigli M Sangiorgi G M Golia B Ricciardelli B Condorelli G Investigators R I Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury 2011 Circulation 124 1260 9 10.1161\/CIRCULATIONAHA.111.030759","DOI":"10.1161\/CIRCULATIONAHA.111.030759"},{"key":"ref198","doi-asserted-by":"crossref","unstructured":"198. Briguori C Visconti G Ricciardelli B Condorelli G Investigators RI(2011)Renal insufficiency following contrast media administration trial II (REMEDIAL II): RenalGuard system in high-risk patients for contrast-induced acute kidney injury: rationale and design EuroIntervention7 6 1117 22 10.4244\/EIJV6I9A194","DOI":"10.4244\/EIJV6I9A194"},{"key":"ref199","doi-asserted-by":"crossref","unstructured":"199. Russo D Testa A Della Volpe L Sansone G Randomised prospective study on renal effects of two different contrast media in humans: protective role of a calcium channel blocker 1990 Nephron 55 254 7","DOI":"10.1159\/000185971"},{"key":"ref200","unstructured":"200. Neumayer H H Junge W Kufner A Wenning A Prevention of radiocontrast-media-induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective randomised clinical trial 1989 Nephrol Dial Transplant 4 1030 6"},{"key":"ref201","doi-asserted-by":"crossref","unstructured":"201. Spangberg-Viklund B Berglund J Nikonoff T Nyberg P Skau T Larsson R Does prophylactic treatment with felodipine, a calcium antagonist, prevent low-osmolar contrast-induced renal dysfunction in hydrated diabetic and nondiabetic patients with normal or moderately reduced renal function? 1996 Scand J Urol Nephrol 30 63 8","DOI":"10.3109\/00365599609182351"},{"key":"ref202","doi-asserted-by":"crossref","unstructured":"202. Pasternak J J Williamson E E Clinical pharmacology, uses, and adverse reactions of iodinated contrast agents: a primer for the non-radiologist 2012 Mayo Clin Proc 87 390 402 10.1016\/j.mayocp.2012.01.012","DOI":"10.1016\/j.mayocp.2012.01.012"}],"container-title":["Journal Of Nephrology Advances"],"language":"en","link":[{"URL":"https:\/\/openaccesspub.org\/article\/141\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openaccesspub.org\/article\/141\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T11:32:50Z","timestamp":1760700770000},"score":0.0,"resource":{"primary":{"URL":"https:\/\/openaccesspub.org\/nephrology-advances\/article\/141"}},"issued":{"date-parts":[[2015]]},"references-count":202,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.14302\/issn.2574-4488.jna-14-601","ISSN":["2574-4488"],"issn-type":[{"value":"2574-4488","type":"electronic"}],"published":{"date-parts":[[2015]]}},{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T01:36:27Z","timestamp":1648690587662},"reference-count":0,"publisher":"Open Access Pub","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JNA"],"DOI":"10.14302\/issn.2574-4488.jna-15-712","type":"journal-article","created":{"date-parts":[[2017,9,10]],"date-time":"2017-09-10T06:21:28Z","timestamp":1505024488000},"page":"42-47","source":"Crossref","is-referenced-by-count":1,"title":["Acute Bilateral Hydronephrosis after the Use of Dapagliflozin"],"prefix":"10.14302","volume":"1","author":[{"given":"Afandi","family":"Bachar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernieh","family":"Bassam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5410","published-online":{"date-parts":[[2016,2,2]]},"container-title":["Journal Of Nephrology Advances"],"deposited":{"date-parts":[[2017,9,10]],"date-time":"2017-09-10T06:21:31Z","timestamp":1505024491000},"score":0.0,"resource":{"primary":{"URL":"http:\/\/openaccesspub.org\/jna\/article\/228"}},"editor":[{"given":"Mohammad","family":"Naghavi-Behzad","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"issued":{"date-parts":[[2016,2,2]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,5,19]]}},"URL":"https:\/\/doi.org\/10.14302\/issn.2574-4488.jna-15-712","ISSN":["2574-4488"],"issn-type":[{"value":"2574-4488","type":"electronic"}],"published":{"date-parts":[[2016,2,2]]}}],"items-per-page":20,"query":{"start-index":0,"search-terms":null}}}